The Role of N⁶-Methyladenosine Modification in Health and Disease

Abstract

Emerging evidence highlights that N⁶-methyladenosine (m⁶A), the most prevalent internal RNA modification in eukaryotes, serves as a critical epitranscriptomic regulator of RNA metabolism. This posttranscriptional modification modulates alternative splicing, nuclear export, stability, and translation, thereby regulating various physiological processes. Notably, dysregulation of m⁶A-associated modifiers (writers/erasers/readers) is implicated in a variety of diseases, such as metabolic disorders and cancer. Despite the rapid progress of m⁶A-mediated emerging therapeutic strategies, there remains an imperative to bridge the gap between basic epitranscriptomics and clinical application. This review systematically depicts recent advances in understanding m⁶A-mediated epitranscriptomic regulation, with particular focus on its dual role in maintaining cellular homeostasis and driving disease progression upon dysregulation, provides a dedicated exploration of m⁶A-regulated mitochondrial remodeling, and outlines cutting-edge technologies for m⁶A mapping and inhibitors targeting m⁶A modifiers. Furthermore, we conduct an in-depth exploration of the existing limitations and therapeutic potential associated with targeting m⁶A modification. Acting as a pivotal link between epitranscriptomics and medicine, m⁶A modification provides novel perspectives for developing precision interventions in complex human diseases.

Keywords

diseases / molecular mechanisms / N⁶-methyladenosine / therapy

References

[1] D. Wiener and S. Schwartz, “The Epitranscriptome Beyond M(6)A,” Nature Reviews Genetics 22, no. 2 (2021): 119–131.

[2] P. C. He and C. He, “m(6) A RNA Methylation: From Mechanisms to Therapeutic Potential,” Embo Journal 40, no. 3 (2021): e105977.

[3] S. Zaccara, R. J. Ries, and S. R. Jaffrey, “Reading, Writing and Erasing mRNA Methylation,” Nature Reviews Molecular Cell Biology 24, no. 10 (2023): 770.

[4] L. Xu, T. Shen, Y. Li, and X. Wu, “The Role of M(6)A Modification in Autoimmunity: Emerging Mechanisms and Therapeutic Implications,” Clinical Reviews in Allergy & Immunology 68, no. 1 (2025): 29.

[5] Y. Liu, Z. Sun, D. Gui, Y. Zhao, and Y. Xu, “RNA Modification in Metabolism,” MedComm 6, no. 3 (2025): e70135.

[6] Y. Qu, N. Gao, S. Zhang, et al., “Role of N6-Methyladenosine RNA Modification in Cancer,” MedComm 5, no. 9 (2024): e715.

[7] S. Wu, S. Zhang, X. Wu, and X. Zhou, “m(6)A RNA Methylation in Cardiovascular Diseases,” Molecular Therapy 28, no. 10 (2020): 2111–2119.

[8] H. Tian, Y. Chen, X. Dong, X. Fan, and R. Jia, “The m6A Hypermethylation-Induced PIR Overexpression Regulates H3K4me3 and Promotes Tumorigenesis of Uveal Melanoma,” Cancer Letters 623 (2025): 217729.

[9] Z. W. Zhang, X. S. Zhao, H. Guo, and X. J. Huang, “The Role of M(6)A Demethylase FTO in Chemotherapy Resistance Mediating Acute Myeloid Leukemia Relapse,” Cell Death Discovery 9, no. 1 (2023): 225.

[10] Y. H. Sun, T. J. Zhao, L. H. Li, Z. Wang, and H. B. Li, “Emerging Role of N(6)-Methyladenosine in the Homeostasis of Glucose Metabolism,” American Journal of Physiology. Endocrinology and Metabolism 326, no. 1 (2024): E1–e13.

[11] P. Bawankar, T. Lence, C. Paolantoni, et al., “Hakai Is Required for Stabilization of Core Components of the M(6)A mRNA Methylation Machinery,” Nature Communications 12, no. 1 (2021): 3778.

[12] M. Zhang, Z. Bodi, K. Mackinnon, et al., “Two Zinc Finger Proteins With Functions in M(6)A Writing Interact With HAKAI,” Nature Communications 13, no. 1 (2022): 1127.

[13] P. Knuckles, T. Lence, I. U. Haussmann, et al., “Zc3h13/Flacc Is Required for Adenosine Methylation by Bridging the mRNA-binding Factor Rbm15/Spenito to the M(6)A Machinery Component Wtap/Fl(2)D,” Genes & Development 32, no. 5-6 (2018): 415–429.

[14] R. Su, L. Dong, Y. Li, et al., “METTL16 exerts an M(6)A-Independent Function to Facilitate Translation and Tumorigenesis,” Nature Cell Biology 24, no. 2 (2022): 205–216.

[15] H. Song, D. Liu, L. Wang, et al., “Methyltransferase Like 7B Is a Potential Therapeutic Target for Reversing EGFR-TKIs Resistance in Lung Adenocarcinoma,” Molecular Cancer 21, no. 1 (2022): 43.

[16] Y. Jin, X. Han, Y. Wang, and Z. Fan, “METTL7A-Mediated m6A Modification of Corin Reverses Bisphosphonates-Impaired Osteogenic Differentiation of Orofacial BMSCs,” International Journal of Oral Science 16, no. 1 (2024): 42.

[17] M. Shen, Y. Li, Y. Wang, et al., “N(6)-Methyladenosine Modification Regulates Ferroptosis Through Autophagy Signaling Pathway in Hepatic Stellate Cells,” Redox Biology 47 (2021): 102151.

[18] G. Zheng, J. A. Dahl, Y. Niu, et al., “ALKBH5 is a Mammalian RNA Demethylase That Impacts RNA Metabolism and Mouse Fertility,” Molecular Cell 49, no. 1 (2013): 18–29.

[19] G. Jia, Y. Fu, X. Zhao, et al., “N6-methyladenosine in Nuclear RNA Is a Major Substrate of the Obesity-Associated FTO,” Nature Chemical Biology 7, no. 12 (2011): 885–887.

[20] L. Li, Y. Sun, W. Zha, L. Li, and H. Li, “Novel Insights Into the N(6)-Methyladenosine RNA Modification and Phytochemical Intervention in Lipid Metabolism,” Toxicology and Applied Pharmacology 457 (2022): 116323.

[21] J. Mauer, X. Luo, A. Blanjoie, et al., “Reversible Methylation of M(6)A(m) in the 5' cap Controls mRNA Stability,” Nature 541, no. 7637 (2017): 371–375.

[22] J. Wei, F. Liu, Z. Lu, et al., “Differential M(6)A, M(6)A(m), and M(1)A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm,” Molecular Cell 71, no. 6 (2018): 973–985.e5.

[23] G. Q. Lai, Y. Li, H. Zhu, et al., “A Covalent Compound Selectively Inhibits RNA Demethylase ALKBH5 Rather Than FTO,” RSC Chemical Biology 5, no. 4 (2024): 335–343.

[24] S. Kaur, N. Y. Tam, M. A. McDonough, C. J. Schofield, and W. S. Aik, “Mechanisms of Substrate Recognition and N6-Methyladenosine Demethylation Revealed by Crystal Structures of ALKBH5-RNA Complexes,” Nucleic Acids Research 50, no. 7 (2022): 4148–4160.

[25] Y. Fu, G. Jia, X. Pang, et al., “FTO-Mediated Formation of N6-Hydroxymethyladenosine and N6-Formyladenosine in Mammalian RNA,” Nature Communications 4 (2013): 1798.

[26] C. Feng, Y. Liu, G. Wang, et al., “Crystal Structures of the Human RNA Demethylase Alkbh5 Reveal Basis for Substrate Recognition,” Journal of Biological Chemistry 289, no. 17 (2014): 11571–11583.

[27] W. Xiao, S. Adhikari, U. Dahal, et al., “Nuclear M(6)A Reader YTHDC1 Regulates mRNA Splicing,” Molecular Cell 61, no. 4 (2016): 507–519.

[28] I. A. Roundtree, G. Z. Luo, Z. Zhang, et al., “YTHDC1 Mediates Nuclear Export of N(6)-Methyladenosine Methylated mRNAs,” Elife 6 (2017): e31311.

[29] P. J. Hsu, Y. Zhu, H. Ma, et al., “Ythdc2 is an N(6)-Methyladenosine Binding Protein That Regulates Mammalian Spermatogenesis,” Cell Research 27, no. 9 (2017): 1115–1127.

[30] X. Wang, B. S. Zhao, I. A. Roundtree, et al., “N(6)-Methyladenosine Modulates Messenger RNA Translation Efficiency,” Cell 161, no. 6 (2015): 1388–1399.

[31] X. Wang, Z. Lu, A. Gomez, et al., “N6-methyladenosine-Dependent Regulation of Messenger RNA Stability,” Nature 505, no. 7481 (2014): 117–120.

[32] H. Du, Y. Zhao, J. He, et al., “YTHDF2 Destabilizes M(6)A-Containing RNA Through Direct Recruitment of the CCR4-NOT Deadenylase Complex,” Nature Communications 7 (2016): 12626.

[33] A. Li, Y. S. Chen, X. L. Ping, et al., “Cytoplasmic M(6)A Reader YTHDF3 Promotes mRNA Translation,” Cell Research 27, no. 3 (2017): 444–447.

[34] H. Shi, X. Wang, Z. Lu, et al., “YTHDF3 Facilitates Translation and Decay of N(6)-Methyladenosine-Modified RNA,” Cell Research 27, no. 3 (2017): 315–328.

[35] C. R. Alarcón, H. Goodarzi, H. Lee, X. Liu, S. Tavazoie, and S. F. Tavazoie, “HNRNPA2B1 Is a Mediator of M(6)A-Dependent Nuclear RNA Processing Events,” Cell 162, no. 6 (2015): 1299–1308.

[36] N. Liu, K. I. Zhou, M. Parisien, Q. Dai, L. Diatchenko, and T. Pan, “N6-Methyladenosine Alters RNA Structure to Regulate Binding of a Low-Complexity Protein,” Nucleic Acids Research 45, no. 10 (2017): 6051–6063.

[37] N. Liu, Q. Dai, G. Zheng, C. He, M. Parisien, and T. Pan, “N(6)-Methyladenosine-Dependent RNA Structural Switches Regulate RNA-Protein Interactions,” Nature 518, no. 7540 (2015): 560–564.

[38] K. I. Zhou, H. Shi, R. Lyu, et al., “Regulation of Co-Transcriptional Pre-mRNA Splicing by M(6)A Through the Low-Complexity Protein hnRNPG,” Molecular Cell 76, no. 1 (2019): 70–81.e9.

[39] H. Huang, H. Weng, W. Sun, et al., “Recognition of RNA N(6)-Methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation,” Nature Cell Biology 20, no. 3 (2018): 285–295.

[40] B. M. Edens, C. Vissers, J. Su, et al., “FMRP Modulates Neural Differentiation Through M(6)A-Dependent mRNA Nuclear Export,” Cell Reports 28, no. 4 (2019): 845–854.e5.

[41] Z. Zou, J. Wei, Y. Chen, et al., “FMRP Phosphorylation Modulates Neuronal Translation Through YTHDF1,” Molecular Cell 83, no. 23 (2023): 4304–4317.e8.

[42] F. Zhang, Y. Kang, M. Wang, et al., “Fragile X Mental Retardation Protein Modulates the Stability of Its m6A-Marked Messenger RNA Targets,” Human Molecular Genetics 27, no. 22 (2018): 3936–3950.

[43] K. D. Meyer, Y. Saletore, P. Zumbo, O. Elemento, C. E. Mason, and S. R. Jaffrey, “Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3' UTRs and near Stop Codons,” Cell 149, no. 7 (2012): 1635–1646.

[44] D. Dominissini, S. Moshitch-Moshkovitz, S. Schwartz, et al., “Topology of the Human and Mouse m6A RNA Methylomes Revealed by m6A-seq,” Nature 485, no. 7397 (2012): 201–206.

[45] Y. L. Weng, X. Wang, R. An, et al., “Epitranscriptomic M(6)A Regulation of Axon Regeneration in the Adult Mammalian Nervous System,” Neuron 97, no. 2 (2018): 313–325.e6.

[46] Y. Zeng, S. Wang, S. Gao, et al., “Refined RIP-seq Protocol for Epitranscriptome Analysis With Low Input Materials,” Plos Biology 16, no. 9 (2018): e2006092.

[47] K. Chen, Z. Lu, X. Wang, et al., “High-Resolution N(6) -Methyladenosine (m(6) A) Map Using Photo-Crosslinking-Assisted M(6) A Sequencing,” Angewandte Chemie 54, no. 5 (2015): 1587–1590.

[48] M. Hafner, M. Landthaler, L. Burger, et al., “Transcriptome-Wide Identification of RNA-Binding Protein and microRNA Target Sites by PAR-CLIP,” Cell 141, no. 1 (2010): 129–141.

[49] Y. Wang, Y. Xiao, S. Dong, Q. Yu, and G. Jia, “Antibody-Free Enzyme-Assisted Chemical Approach for Detection of N(6)-Methyladenosine,” Nature Chemical Biology 16, no. 8 (2020): 896–903.

[50] B. Linder, A. V. Grozhik, A. O. Olarerin-George, C. Meydan, C. E. Mason, and S. R. Jaffrey, “Single-Nucleotide-Resolution Mapping of m6A and m6Am Throughout the Transcriptome,” Nature Methods 12, no. 8 (2015): 767–772.

[51] J. T. Roberts, A. M. Porman, and A. M. Johnson, “Identification of M(6)A Residues at Single-Nucleotide Resolution Using eCLIP and an Accessible Custom Analysis Pipeline,” RNA 27, no. 4 (2021): 527–541.

[52] C. W. Q. Koh, Y. T. Goh, and W. S. S. Goh, “Atlas of Quantitative Single-Base-Resolution N(6)-Methyl-Adenine Methylomes,” Nature Communications 10, no. 1 (2019): 5636.

[53] M. A. Garcia-Campos, S. Edelheit, U. Toth, et al., “Deciphering the “M(6)A Code” via Antibody-Independent Quantitative Profiling,” Cell 178, no. 3 (2019): 731–747.e16.

[54] Z. Zhang, L. Q. Chen, Y. L. Zhao, et al., “Single-Base Mapping of M(6)A by an Antibody-Independent Method,” Science Advances 5, no. 7 (2019): eaax0250.

[55] K. D. Meyer, “DART-seq: An Antibody-Free Method for Global M(6)A Detection,” Nature Methods 16, no. 12 (2019): 1275–1280.

[56] H. Zhu, X. Yin, C. L. Holley, and K. D. Meyer, “Improved Methods for Deamination-Based M(6)A Detection,” Frontiers in Cell and Developmental Biology 10 (2022): 888279.

[57] Y. L. Xiao, S. Liu, R. Ge, et al., “Transcriptome-wide Profiling and Quantification of N(6)-Methyladenosine by Enzyme-Assisted Adenosine Deamination,” Nature Biotechnology 41, no. 7 (2023): 993–1003.

[58] C. Liu, H. Sun, Y. Yi, et al., “Absolute Quantification of Single-Base M(6)A Methylation in the Mammalian Transcriptome Using GLORI,” Nature Biotechnology 41, no. 3 (2023): 355–366.

[59] P. Wang, C. Ye, M. Zhao, B. Jiang, and C. He, “Small-Molecule-Catalysed Deamination Enables Transcriptome-Wide Profiling of N(6)-Methyladenosine in RNA,” Nature Chemistry 17, no. 7 (2025): 1042–1052.

[60] X. Shu, J. Cao, M. Cheng, et al., “A Metabolic Labeling Method Detects M(6)A Transcriptome-Wide at Single Base Resolution,” Nature Chemical Biology 16, no. 8 (2020): 887–895.

[61] D. Clyde, “New Tools for Transcriptome-Wide Mapping of M(6)A,” Nature Reviews Genetics 21, no. 7 (2020): 387.

[62] K. Hartstock, B. S. Nilges, A. Ovcharenko, et al., “Enzymatic or in Vivo Installation of Propargyl Groups in Combination With Click Chemistry for the Enrichment and Detection of Methyltransferase Target Sites in RNA,” Angewandte Chemie 57, no. 21 (2018): 6342–6346.

[63] K. Hartstock, N. A. Kueck, P. Spacek, et al., “MePMe-seq: Antibody-Free Simultaneous M(6)A and M(5)C Mapping in mRNA by Metabolic Propargyl Labeling and Sequencing,” Nature Communications 14, no. 1 (2023): 7154.

[64] S. Mikutis, M. Gu, E. Sendinc, et al., “meCLICK-Seq, a Substrate-Hijacking and RNA Degradation Strategy for the Study of RNA Methylation,” ACS Central Science 6, no. 12 (2020): 2196–2208.

[65] H. C. O'Farrell, N. Pulicherla, P. M. Desai, and J. P. Rife, “Recognition of a Complex Substrate by the KsgA/Dim1 family of Enzymes Has Been Conserved throughout Evolution,” RNA 12, no. 5 (2006): 725–733.

[66] L. Hu, S. Liu, Y. Peng, et al., “m(6)A RNA Modifications Are Measured at Single-Base Resolution Across the Mammalian Transcriptome,” Nature Biotechnology 40, no. 8 (2022): 1210–1219.

[67] T. Hong, Y. Yuan, Z. Chen, et al., “Precise Antibody-Independent m6A Identification via 4SedTTP-Involved and FTO-Assisted Strategy at Single-Nucleotide Resolution,” Journal of the American Chemical Society 140, no. 18 (2018): 5886–5889.

[68] Y. Xie, S. Han, Q. Li, et al., “Transcriptome-Wide Profiling of N (6)-Methyladenosine via a Selective Chemical Labeling Method,” Chemical Science 13, no. 41 (2022): 12149–12157.

[69] M. Tegowski and K. D. Meyer, “Detection of M(6)A in Single Cultured Cells Using scDART-seq,” STAR Protocols 3, no. 3 (2022): 101646.

[70] M. Tegowski, M. N. Flamand, and K. D. Meyer, “scDART-seq Reveals Distinct M(6)A Signatures and mRNA Methylation Heterogeneity in Single Cells,” Molecular Cell 82, no. 4 (2022): 868–878.e10.

[71] H. Yao, C. C. Gao, D. Zhang, et al., “scm(6)A-seq Reveals Single-Cell Landscapes of the Dynamic M(6)A During Oocyte Maturation and Early Embryonic Development,” Nature Communications 14, no. 1 (2023): 315.

[72] Y. Li, Y. Wang, M. Vera-Rodriguez, et al., “Single-Cell M(6)A Mapping in Vivo Using picoMeRIP-seq,” Nature Biotechnology 42, no. 4 (2024): 591–596.

[73] K. Hamashima, K. W. Wong, T. W. Sam, et al., “Single-Nucleus Multiomic Mapping of M(6)A Methylomes and Transcriptomes in Native Populations of Cells With sn-m6A-CT,” Molecular Cell (2023).

[74] T. Shan, F. Liu, M. Wen, et al., “m(6)A Modification Negatively Regulates Translation by Switching mRNA From Polysome to P-Body via IGF2BP3,” Molecular Cell 83, no. 24 (2023): 4494–4508.e6.

[75] S. Mitschka and C. Mayr, “Context-Specific Regulation and Function of mRNA Alternative Polyadenylation,” Nature Reviews Molecular Cell Biology 23, no. 12 (2022): 779–796.

[76] B. Molinie, J. Wang, K. S. Lim, et al., “m(6)A-LAIC-seq Reveals the Census and Complexity of the m(6)A Epitranscriptome,” Nature Methods 13, no. 8 (2016): 692–698.

[77] D. R. Garalde, E. A. Snell, D. Jachimowicz, et al., “Highly Parallel Direct RNA Sequencing on an Array of Nanopores,” Nature Methods 15, no. 3 (2018): 201–206.

[78] Y. Wang, Y. Zhao, A. Bollas, Y. Wang, and K. F. Au, “Nanopore Sequencing Technology, Bioinformatics and Applications,” Nature Biotechnology 39, no. 11 (2021): 1348–1365.

[79] W. Stephenson, R. Razaghi, S. Busan, K. M. Weeks, W. Timp, and P. Smibert, “Direct Detection of RNA Modifications and Structure Using Single-Molecule Nanopore Sequencing,” Cell Genomics 2, no. 2 (2022): 100097.

[80] T. Ohshiro, M. Konno, A. Asai, et al., “Single-Molecule RNA Sequencing for Simultaneous Detection of m6A and 5mC,” Scientific Reports 11, no. 1 (2021): 19304.

[81] A. M. Price, K. E. Hayer, A. B. R. McIntyre, et al., “Direct RNA Sequencing Reveals M(6)A Modifications on Adenovirus RNA Are Necessary for Efficient Splicing,” Nature Communications 11, no. 1 (2020): 6016.

[82] P. Jenjaroenpun, T. Wongsurawat, T. D. Wadley, et al., “Decoding the Epitranscriptional Landscape From Native RNA Sequences,” Nucleic Acids Research 49, no. 2 (2021): e7.

[83] M. Piechotta, I. S. Naarmann-de Vries, Q. Wang, J. Altmüller, and C. Dieterich, “RNA Modification Mapping With JACUSA2,” Genome Biology 23, no. 1 (2022): 115.

[84] D. A. Lorenz, S. Sathe, J. M. Einstein, and G. W. Yeo, “Direct RNA Sequencing Enables M(6)A Detection in Endogenous Transcript Isoforms at Base-Specific Resolution,” RNA 26, no. 1 (2020): 19–28.

[85] P. N. Pratanwanich, F. Yao, Y. Chen, et al., “Identification of Differential RNA Modifications From Nanopore Direct RNA Sequencing With xPore,” Nature Biotechnology 39, no. 11 (2021): 1394–1402.

[86] H. Qin, L. Ou, J. Gao, et al., “DENA: Training an Authentic Neural Network Model Using Nanopore Sequencing Data of Arabidopsis Transcripts for Detection and Quantification of N(6)-Methyladenosine on RNA,” Genome Biology 23, no. 1 (2022): 25.

[87] P. Acera Mateos, A. J. Sethi, A. Ravindran, et al., “Prediction of m6A and m5C at Single-Molecule Resolution Reveals a Transcriptome-Wide Co-Occurrence of RNA Modifications,” Nature Communications 15, no. 1 (2024): 3899.

[88] A. Leger, P. P. Amaral, L. Pandolfini, et al., “RNA Modifications Detection by Comparative Nanopore Direct RNA Sequencing,” Nature Communications 12, no. 1 (2021): 7198.

[89] W. Guo, Z. Ren, X. Huang, et al., “Single-Molecule M(6)A Detection Empowered by Endogenous Labeling Unveils Complexities Across RNA Isoforms,” Molecular Cell 85, no. 6 (2025): 1233–1246.e7.

[90] J. Zhang, L. Tong, Y. Liu, et al., “The Regulatory Role of M(6)A Modification in the Maintenance and Differentiation of Embryonic Stem Cells,” Genes Diseases 11, no. 5 (2024): 101199.

[91] J. Yang, Y. Yang, X. Zhang, et al., “HDAC2-Mediated Recruitment of METTL3 to Chromatin Regulates Human Embryonic Stem Cell Differentiation,” Cell Reports 44, no. 10 (2025): 116414.

[92] B. Feng, Y. Chen, H. Tu, et al., “Transcriptomic Analysis of the m6A Reader YTHDF2 in the Maintenance and Differentiation of Human Embryonic Stem Cells,” Stem Cells 43, no. 7 (2025): sxaf032.

[93] Z. Liang, T. Huang, W. Li, et al., “ALKBH5 governs Human Endoderm Fate by Regulating the DKK1/4-Mediated Wnt/β-Catenin Activation,” Nucleic Acids Research 52, no. 18 (2024): 10879–10896.

[94] F. Zhang, Y. Fu, D. Jimenez-Cyrus, et al., “m(6)A/YTHDF2-Mediated mRNA Decay Targets TGF-β Signaling to Suppress the Quiescence Acquisition of Early Postnatal Mouse Hippocampal NSCs,” Cell Stem Cell 32, no. 1 (2025): 144–156.e8.

[95] L. P. Vu, B. F. Pickering, Y. Cheng, et al., “The N(6)-Methyladenosine (m(6)A)-Forming Enzyme METTL3 Controls Myeloid Differentiation of Normal Hematopoietic and Leukemia Cells,” Nature Medicine 23, no. 11 (2017): 1369–1376.

[96] H. Lee, S. Bao, Y. Qian, et al., “Stage-Specific Requirement for Mettl3-Dependent M(6)A mRNA Methylation During Haematopoietic Stem Cell Differentiation,” Nature Cell Biology 21, no. 6 (2019): 700–709.

[97] Y. Cheng, H. Luo, F. Izzo, et al., “m(6)A RNA Methylation Maintains Hematopoietic Stem Cell Identity and Symmetric Commitment,” Cell Reports 28, no. 7 (2019): 1703–1716.e6.

[98] X. Zhang, T. Cong, L. Wei, et al., “YTHDF3 Modulates Hematopoietic Stem Cells by Recognizing RNA M(6)A Modification on Ccnd1,” Haematologica 107, no. 10 (2022): 2381–2394.

[99] H. Wang, H. Zuo, J. Liu, et al., “Loss of YTHDF2-Mediated M(6)A-Dependent mRNA Clearance Facilitates Hematopoietic Stem Cell Regeneration,” Cell Research 28, no. 10 (2018): 1035–1038.

[100] Z. Li, P. Qian, W. Shao, et al., “Suppression of M(6)A Reader Ythdf2 Promotes Hematopoietic Stem Cell Expansion,” Cell Research 28, no. 9 (2018): 904–917.

[101] Y. Wu, L. Xie, M. Wang, et al., “Mettl3-Mediated M(6)A RNA Methylation Regulates the Fate of Bone Marrow Mesenchymal Stem Cells and Osteoporosis,” Nature Communications 9, no. 1 (2018): 4772.

[102] Y. You, J. Liu, L. Zhang, et al., “WTAP-Mediated M(6)A Modification Modulates Bone Marrow Mesenchymal Stem Cells Differentiation Potential and Osteoporosis,” Cell Death & Disease 14, no. 1 (2023): 33.

[103] L. Lu, L. Wang, M. Yang, and H. Wang, “Role of METTL16 in PPARγ Methylation and Osteogenic Differentiation,” Cell Death & Disease 16, no. 1 (2025): 271.

[104] L. S. Chen, M. Zhang, P. Chen, et al., “The M(6)A Demethylase FTO Promotes the Osteogenesis of Mesenchymal Stem Cells by Downregulating PPARG,” Acta Pharmacologica Sinica 43, no. 5 (2022): 1311–1323.

[105] Z. Li, P. Wang, J. Li, et al., “The N(6)-Methyladenosine Demethylase ALKBH5 Negatively Regulates the Osteogenic Differentiation of Mesenchymal Stem Cells Through PRMT6,” Cell Death & Disease 12, no. 6 (2021): 578.

[106] T. Liu, X. Zheng, C. Wang, et al., “The M(6)A “Reader” YTHDF1 Promotes Osteogenesis of Bone Marrow Mesenchymal Stem Cells Through Translational Control of ZNF839,” Cell Death & Disease 12, no. 11 (2021): 1078.

[107] B. Zhou, X. Feng, C. Han, et al., “YTHDF3 Regulates IL32 mRNA Stability to Promote Osteogenic Differentiation of Bone Mesenchymal Stem Cells in Ankylosing Spondylitis,” Journal of Translational Medicine 23, no. 1 (2025): 604.

[108] H. B. Li, J. Tong, S. Zhu, et al., “m(6)A mRNA Methylation Controls T Cell Homeostasis by Targeting the IL-7/STAT5/SOCS Pathways,” Nature 548, no. 7667 (2017): 338–342.

[109] J. Zhou, X. Zhang, J. Hu, et al., “m(6)A Demethylase ALKBH5 Controls CD4(+) T Cell Pathogenicity and Promotes Autoimmunity,” Science Advances 7, no. 25 (2021): eabg0470.

[110] T. X. Lu, Z. Zheng, L. Zhang, et al., “A New Model of Spontaneous Colitis in Mice Induced by Deletion of an RNA M(6)A Methyltransferase Component METTL14 in T Cells,” Cellular and Molecular Gastroenterology and Hepatology 10, no. 4 (2020): 747–761.

[111] Y. Yao, Y. Yang, W. Guo, et al., “METTL3-Dependent M(6)A Modification Programs T Follicular Helper Cell Differentiation,” Nature Communications 12, no. 1 (2021): 1333.

[112] W. Guo, Z. Wang, Y. Zhang, et al., “Mettl3-dependent M(6)A Modification Is Essential for Effector Differentiation and Memory Formation of CD8(+) T Cells,” Science Bulletin 69, no. 1 (2024): 82–96.

[113] Z. Zheng, L. Zhang, X. L. Cui, et al., “Control of Early B Cell Development by the RNA N(6)-Methyladenosine Methylation,” Cell Reports 31, no. 13 (2020): 107819.

[114] N. S. De Silva and U. Klein, “Dynamics of B Cells in Germinal Centres,” Nature Reviews Immunology 15, no. 3 (2015): 137–148.

[115] S. Finkin, H. Hartweger, T. Y. Oliveira, E. E. Kara, and M. C. Nussenzweig, “Protein Amounts of the MYC Transcription Factor Determine Germinal Center B Cell Division Capacity,” Immunity 51, no. 2 (2019): 324–336.e5.

[116] A. C. Grenov, L. Moss, S. Edelheit, et al., “The Germinal Center Reaction Depends on RNA Methylation and Divergent Functions of Specific Methyl Readers,” Journal of Experimental Medicine 218, no. 10 (2021): e20210360.

[117] S. Lu, X. Wei, H. Zhu, et al., “RNA N(6)-Methyladenosine Reader Protein YTHDF1 Promotes Plasma Cell Differentiation via IRF4 Regulation in Systemic Lupus Erythematosus,” Experimental & Molecular Medicine 57, no. 11 (2025): 2574–2587.

[118] T. Huang, S. Chen, K. Ding, et al., “METTL3/ALKBH5-Mediated N6-Methyladenosine Modification Drives Macrophage M1 Polarization via the SLC15A3-TASL-IRF5 Signaling Axis in Psoriasis,” Advanced Science (Weinheim) 12, no. 36 (2025): e01408.

[119] H. Wang, X. Hu, M. Huang, et al., “Mettl3-mediated mRNA M(6)A Methylation Promotes Dendritic Cell Activation,” Nature Communications 10, no. 1 (2019): 1898.

[120] D. Han, J. Liu, C. Chen, et al., “Anti-Tumour Immunity Controlled Through mRNA M(6)A Methylation and YTHDF1 in Dendritic Cells,” Nature 566, no. 7743 (2019): 270–274.

[121] S. Ma, J. Yan, T. Barr, et al., “The RNA m6A Reader YTHDF2 Controls NK Cell Antitumor and Antiviral Immunity,” Journal of Experimental Medicine 218, no. 8 (2021): e20210360.

[122] X. Liu, M. Feng, X. Hao, et al., “m6A Methylation Regulates Hypoxia-Induced Pancreatic Cancer Glycolytic Metabolism Through ALKBH5-HDAC4-HIF1α Positive Feedback Loop,” Oncogene 42, no. 25 (2023): 2047–2060.

[123] Q. Jiang, X. Chen, K. Gong, Z. Xu, L. Chen, and F. Zhang, “M6a Demethylase FTO Regulates the Oxidative Stress, Mitochondrial Biogenesis of Cardiomyocytes and PGC-1a Stability in Myocardial Ischemia-Reperfusion Injury,” Redox Report: Communications in Free Radical Research 30, no. 1 (2025): 2454892.

[124] Y. Chen, Y. Liu, W. Tu, Y. Chen, C. Xu, and C. Huang, “m6A Demethylase FTO Transcriptionally Activated by SP1 Improves Ischemia Reperfusion-Triggered Acute Kidney Injury by Activating Ambra1/ULK1-Mediated Autophagy,” Faseb Journal 38, no. 20 (2024): e70118.

[125] J. Man, Q. Zhang, T. Zhao, et al., “YTHDF2 Phase Separation Promotes Arsenite-Induced Oxidative Stress by Facilitating YTHDF2-Mediated PIK3R2 mRNA Degradation,” International Journal of Biological Macromolecules 318, no. Pt 1 (2025): 144936.

[126] K. Timcheva, S. Dufour, L. Touat-Todeschini, et al., “Chromatin-Associated YTHDC1 Coordinates Heat-Induced Reprogramming of Gene Expression,” Cell Reports 41, no. 11 (2022): 111784.

[127] B. Lee, S. Lee, and J. Shim, “YTHDF2 Suppresses Notch Signaling Through Post-Transcriptional Regulation on Notch1,” International Journal of Biological Sciences 17, no. 14 (2021): 3776–3785.

[128] J. Zhou, J. Wan, X. Gao, X. Zhang, S. R. Jaffrey, and S. B. Qian, “Dynamic M(6)A mRNA Methylation Directs Translational Control of Heat Shock Response,” Nature 526, no. 7574 (2015): 591–594.

[129] J. Cen, D. Zhao, X. Shi, et al., “N6-Methyladenosine-Mediated Upregulation of MANF Promotes ER Stress Resistance in Renal Cell Carcinoma,” Cell Death & Disease 16, no. 1 (2025): 486.

[130] L. Chen, K. Sun, W. Qin, et al., “LIMK1 m(6)A-RNA Methylation Recognized by YTHDC2 Induces 5-FU Chemoresistance in Colorectal Cancer via Endoplasmic Reticulum Stress and Stress Granule Formation,” Cancer Letters 576 (2023): 216420.

[131] K. Mo, Y. Chu, Y. Liu, et al., “Targeting hnRNPC Suppresses Thyroid Follicular Epithelial Cell Apoptosis and Necroptosis Through m(6)A-Modified ATF4 in Autoimmune Thyroid Disease,” Pharmacological Research 196 (2023): 106933.

[132] Q. Y. Du, F. C. Huo, W. Q. Du, et al., “METTL3 Potentiates Progression of Cervical Cancer by Suppressing ER Stress via Regulating m6A Modification of TXNDC5 mRNA,” Oncogene 41, no. 39 (2022): 4420–4432.

[133] X. Cao, Y. Shu, Y. Chen, et al., “Mettl14-Mediated M(6)A Modification Facilitates Liver Regeneration by Maintaining Endoplasmic Reticulum Homeostasis,” Cellular and Molecular Gastroenterology and Hepatology 12, no. 2 (2021): 633–651.

[134] S. Wang, S. Chen, J. Sun, et al., “m(6)a Modification-Tuned Sphingolipid Metabolism Regulates Postnatal Liver Development in Male Mice,” Nature Metabolism 5, no. 5 (2023): 842–860.

[135] X. Wang, J. Wang, X. Zhao, et al., “METTL3-Mediated m6A Modification of SIRT1 mRNA Inhibits Progression of Endometriosis by Cellular Senescence Enhancing,” Journal of Translational Medicine 21, no. 1 (2023): 407.

[136] Z. Chen, J. Zhou, Y. Wu, et al., “METTL3 promotes Cellular Senescence of Colorectal Cancer via Modulation of CDKN2B Transcription and mRNA Stability,” Oncogene 43, no. 13 (2024): 976–991.

[137] Y. Wang, Y. Chen, H. Xiao, et al., “METTL3-Mediated m6A Modification Increases Hspa1a Stability to Inhibit Osteoblast Aging,” Cell Death Discovery 10, no. 1 (2024): 155.

[138] X. Chen, W. Gong, X. Shao, et al., “METTL3-mediated M(6)A Modification of ATG7 Regulates Autophagy-GATA4 Axis to Promote Cellular Senescence and Osteoarthritis Progression,” Annals of the Rheumatic Diseases 81, no. 1 (2022): 87–99.

[139] L. Chen, C. Zhang, Y. Ge, et al., “PRKN-Mediated Ubiquitin-Proteasome Degradation of METTL3 Promotes Cellular Senescence,” Aging Cell 25, no. 1 (2026): e70347.

[140] X. Liu, H. Liu, Y. Lin, et al., “Deletion of METTL14, a Key Methylation Regulator, Attenuates Vascular Ageing,” European Heart Journal 46, no. 45 (2025): 4953–4968.

[141] L. Zhou, Y. Zhong, F. Wang, et al., “WTAP Mediated N6-Methyladenosine RNA Modification of ELF3 Drives Cellular Senescence by Upregulating IRF8,” International Journal of Biological Sciences 20, no. 5 (2024): 1763–1777.

[142] L. Chen, Z. Chen, J. Mo, et al., “Reversible ALKBH5 Cytosolic Aggregation Accelerates Cellular Senescence,” Cell Death and Differentiation 33, no. 1 (2026): 171–187.

[143] R. Gao, J. Shi, Y. Lyu, et al., “ALKBH5 Regulates Macrophage Senescence and Accelerates Atherosclerosis by Promoting CCL5 M(6)A Modification,” Arteriosclerosis, Thrombosis, and Vascular Biology 45, no. 6 (2025): 928–944.

[144] H. Nie, T. Ji, and Z. Wan, “ATF3 Deficiency Exacerbates Ageing-Induced Atherosclerosis and Clinical Intervention Strategy,” Advanced Science (Weinheim) 12, no. 37 (2025): e02249.

[145] H. Hu, Z. Li, X. Xie, et al., “Insights Into the Role of RNA M(6)A Modification in the Metabolic Process and Related Diseases,” Genes Diseases 11, no. 4 (2024): 101011.

[146] C. Cheng, F. Yu, G. Yuan, and J. Jia, “Update on N6-Methyladenosine Methylation in Obesity-Related Diseases,” Obesity (Silver Spring, Md) 32, no. 2 (2024): 240–251.

[147] Y. F. Wang, W. L. Zhang, Z. X. Li, et al., “METTL14 Downregulation Drives S100A4(+) Monocyte-Derived Macrophages via MyD88/NF-κB Pathway to Promote MAFLD Progression,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 91.

[148] Q. Zheng, X. Zhong, Q. Kang, et al., “METTL14-Induced M(6)A Methylation Increases G6pc Biosynthesis, Hepatic Glucose Production and Metabolic Disorders in Obesity,” Advanced Science (Weinheim) 12, no. 22 (2025): e2417355.

[149] Y. Li, Q. Zhang, G. Cui, et al., “m(6)A Regulates Liver Metabolic Disorders and Hepatogenous Diabetes,” Genomics, Proteomics & Bioinformatics 18, no. 4 (2020): 371–383.

[150] L. Li, Y. Sun, L. Li, et al., “The Deficiency of ALKBH5 Contributes to Hepatic Lipid Deposition by Impairing VPS11-Dependent Autophagic Flux,” FEBS Journal 291, no. 23 (2024): 5256–5275.

[151] K. Ding, Z. Zhang, Z. Han, et al., “Liver ALKBH5 Regulates Glucose and Lipid Homeostasis Independently Through GCGR and mTORC1 Signaling,” Science 387, no. 6737 (2025): eadp4120.

[152] B. Zhou, C. Liu, L. Xu, et al., “N(6) -Methyladenosine Reader Protein YT521-B Homology Domain-Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes,” Hepatology 73, no. 1 (2021): 91–103.

[153] Q. Kang, X. Zhu, D. Ren, et al., “Adipose METTL14-Elicited N(6)-Methyladenosine Promotes Obesity, Insulin Resistance, and NAFLD Through Suppressing β Adrenergic Signaling and Lipolysis,” Advanced Science (Weinheim) 10, no. 28 (2023): e2301645.

[154] L. Xiao, D. F. De Jesus, C. W. Ju, et al., “m(6)A mRNA Methylation in Brown Fat Regulates Systemic Insulin Sensitivity via an Inter-Organ Prostaglandin Signaling Axis Independent of UCP1,” Cell Metabolism 36, no. 10 (2024): 2207–2227.e9.

[155] L. Xiao, D. F. De Jesus, C. W. Ju, et al., “Divergent Roles of M(6)A in Orchestrating Brown and White Adipocyte Transcriptomes and Systemic Metabolism,” Nature Communications 16, no. 1 (2025): 533.

[156] D. F. De Jesus, Z. Zhang, N. K. Brown, et al., “Redox Regulation of M(6)A Methyltransferase METTL3 in β-Cells Controls the Innate Immune Response in Type 1 Diabetes,” Nature Cell Biology 26, no. 3 (2024): 421–437.

[157] C. Wang, S. Shen, J. Kang, et al., “METTL3 Is Essential for Exercise Benefits in Diabetic Cardiomyopathy,” Circulation 152, no. 5 (2025): 327–345.

[158] L. Jiang, X. Liu, X. Hu, et al., “METTL3-mediated M(6)A Modification of TIMP2 mRNA Promotes Podocyte Injury in Diabetic Nephropathy,” Molecular Therapy 30, no. 4 (2022): 1721–1740.

[159] L. Suo, C. Liu, Q. Y. Zhang, et al., “METTL3-Mediated N(6)-Methyladenosine Modification Governs Pericyte Dysfunction During Diabetes-induced Retinal Vascular Complication,” Theranostics 12, no. 1 (2022): 277–289.

[160] X. Li, Y. Yang, and Z. Chen, “Downregulation of the M(6)A Reader Protein YTHDC1 Leads to Islet β-Cell Failure and Diabetes,” Metabolism 138 (2023): 155339.

[161] D. Liang, W. J. Lin, M. Ren, et al., “m(6)a Reader YTHDC1 Modulates Autophagy by Targeting SQSTM1 in Diabetic Skin,” Autophagy 18, no. 6 (2022): 1318–1337.

[162] C. Zhou, X. She, C. Gu, et al., “FTO Fuels Diabetes-Induced Vascular Endothelial Dysfunction Associated With Inflammation by Erasing m6A Methylation of TNIP1,” Journal of Clinical Investigation 133, no. 19 (2023): e160517.

[163] C. Wang, N. Xu, X. Zhong, et al., “ALKBH5 facilitates Tumor Progression via an m6A-YTHDC1-Dependent Mechanism in Glioma,” Cancer Letters 612 (2025): 217439.

[164] M. Xue, L. Dong, H. Zhang, et al., “METTL16 promotes Liver Cancer Stem Cell Self-Renewal via Controlling Ribosome Biogenesis and mRNA Translation,” Journal of Hematology & Oncology 17, no. 1 (2024): 7.

[165] J. Li, G. Xie, Y. Tian, et al., “RNA M(6)A Methylation Regulates Dissemination of Cancer Cells by Modulating Expression and Membrane Localization of β-Catenin,” Molecular Therapy 30, no. 4 (2022): 1578–1596.

[166] B. Li, X. Xiong, J. Xu, et al., “METTL3-Mediated M(6)A Modification of lncRNA TSPAN12 Promotes Metastasis of Hepatocellular Carcinoma Through SENP1-Depentent deSUMOylation of EIF3I,” Oncogene 43, no. 14 (2024): 1050–1062.

[167] Z. Liu, T. Sun, C. Piao, Z. Zhang, and C. Kong, “METTL14-Mediated N(6)-Methyladenosine Modification of ITGB4 mRNA Inhibits Metastasis of Clear Cell Renal Cell Carcinoma,” Cell Communication and Signaling: CCS 20, no. 1 (2022): 36.

[168] Z. Zheng, F. Lin, B. Zhao, et al., “ALKBH5 Suppresses Gastric Cancer Tumorigenesis and Metastasis by Inhibiting the Translation of Uncapped WRAP53 RNA Isoforms in an m6A-Dependent Manner,” Molecular Cancer 24, no. 1 (2025): 19.

[169] Y. Hu, C. Gong, Z. Li, et al., “Demethylase ALKBH5 Suppresses Invasion of Gastric Cancer via PKMYT1 m6A Modification,” Molecular Cancer 21, no. 1 (2022): 34.

[170] Y. Zhao, X. Hu, H. Yu, H. Sun, L. Zhang, and C. Shao, “The FTO Mediated N6-Methyladenosine Modification of DDIT4 Regulation With Tumorigenesis and Metastasis in Prostate Cancer,” Research (Washington, DC) 7 (2024): 0313.

[171] Z. Chen, X. Zhong, M. Xia, et al., “FTO/IGF2BP2-Mediated N6 Methyladenosine Modification in Invasion and Metastasis of Thyroid Carcinoma via CDH12,” Cell Death & Disease 15, no. 10 (2024): 733.

[172] B. Tan, K. Zhou, W. Liu, et al., “RNA N(6) -Methyladenosine Reader YTHDC1 Is Essential for TGF-Beta-Mediated Metastasis of Triple Negative Breast Cancer,” Theranostics 12, no. 13 (2022): 5727–5743.

[173] H. Chen, L. Lin, Z. Qiao, et al., “YTHDF3 Drives Tumor Growth and Metastasis by Recruiting eIF4B to Promote Notch2 Translation in Breast Cancer,” Cancer Letters 614 (2025): 217534.

[174] H. Han, Y. Li, Z. Lin, et al., “ALKBH5 suppresses M(6)A mRNA Modification of FOXM1 to Drive Cetuximab Resistance in KRAS-Mutant Colorectal Cancer,” Oncogene 44, no. 35 (2025): 3225–3238.

[175] F. Yu, S. Zheng, C. Yu, et al., “KRAS Mutants Confer Platinum Resistance by Regulating ALKBH5 Posttranslational Modifications in Lung Cancer,” Journal of Clinical Investigation 135, no. 6 (2025): e185149.

[176] X. Jin, Y. Lv, F. Bie, et al., “METTL3 Confers Oxaliplatin Resistance Through the Activation of G6PD-Enhanced Pentose Phosphate Pathway in Hepatocellular Carcinoma,” Cell Death and Differentiation 32, no. 3 (2025): 466–479.

[177] M. Wang, F. Zou, S. Wang, et al., “CRTC2 Forms Co-Condensates With YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance,” Cancer Research 85, no. 11 (2025): 2046–2066.

[178] J. Miao, X. Jiang, and S. Wang, “YTHDF1-Mediated m6A Modification Promotes Cisplatin Resistance in Ovarian Cancer via the FZD7/Wnt/β-Catenin Pathway,” Apoptosis 30, no. 5-6 (2025): 1525–1546.

[179] Q. Song, W. Wang, H. Yu, et al., “IGF2BP3 Promotes the Proliferation and Cisplatin Resistance of Bladder Cancer by Enhancing the mRNA Stability of CDK6 in an m6A Dependent Manner,” International Journal of Biological Sciences 21, no. 5 (2025): 2048–2066.

[180] J. Wen, L. Xue, Y. Wei, et al., “YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis,” Advanced Science (Weinheim) 11, no. 13 (2024): e2307242.

[181] K. Lin, X. Lin, and F. Luo, “IGF2BP3 Boosts Lactate Generation to Accelerate Gastric Cancer Immune Evasion,” Apoptosis 29, no. 11-12 (2024): 2147–2160.

[182] X. Li, G. Yang, L. Ma, B. Tang, and T. Tao, “N(6)-Methyladenosine (m(6)A) Writer METTL5 Represses the Ferroptosis and Antitumor Immunity of Gastric Cancer,” Cell Death Discovery 10, no. 1 (2024): 402.

[183] F. Dong, X. Qin, B. Wang, et al., “ALKBH5 Facilitates Hypoxia-Induced Paraspeckle Assembly and IL8 Secretion to Generate an Immunosuppressive Tumor Microenvironment,” Cancer Research 81, no. 23 (2021): 5876–5888.

[184] X. Qiu, S. Yang, S. Wang, et al., “M(6)A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma,” Cancer Research 81, no. 18 (2021): 4778–4793.

[185] B. Lian, S. Yan, J. Li, Z. Bai, and J. Li, “HNRNPC Promotes Collagen Fiber Alignment and Immune Evasion in Breast Cancer via Activation of the VIRMA-Mediated TFAP2A/DDR1 Axis,” Molecular Medicine 29, no. 1 (2023): 103.

[186] R. Tang, Z. Zhang, X. Liu, et al., “Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism,” Gastroenterology 169, no. 4 (2025): 615–631.e32.

[187] I. Livneh, S. Moshitch-Moshkovitz, N. Amariglio, G. Rechavi, and D. Dominissini, “The M(6)A Epitranscriptome: Transcriptome Plasticity in Brain Development and Function,” Nature Reviews Neuroscience 21, no. 1 (2020): 36–51.

[188] M. Song, F. Yi, F. Zeng, et al., “USP18 Stabilized FTO Protein to Activate Mitophagy in Ischemic Stroke through Repressing m6A Modification of SIRT6,” Molecular Neurobiology 61, no. 9 (2024): 6658–6674.

[189] Q. S. Wang, R. J. Xiao, J. Peng, Z. T. Yu, J. Q. Fu, and Y. Xia, “Bone Marrow Mesenchymal Stem Cell-Derived Exosomal KLF4 Alleviated Ischemic Stroke through Inhibiting N6-Methyladenosine Modification Level of Drp1 by Targeting lncRNA-ZFAS1,” Molecular Neurobiology 60, no. 7 (2023): 3945–3962.

[190] Y. Zhang and X. Gong, “Fat Mass and Obesity Associated Protein Inhibits Neuronal Ferroptosis via the FYN/Drp1 Axis and Alleviate Cerebral Ischemia/Reperfusion Injury,” CNS Neuroscience & Therapeutics 30, no. 3 (2024): e14636.

[191] Y. D. Du, W. Y. Guo, C. H. Han, et al., “N6-Methyladenosine Demethylase FTO Impairs Hepatic Ischemia-Reperfusion Injury via Inhibiting Drp1-Mediated Mitochondrial Fragmentation,” Cell Death & Disease 12, no. 5 (2021): 442.

[192] Y. Geng, X. Long, Y. Zhang, et al., “FTO-Targeted siRNA Delivery by MSC-Derived Exosomes Synergistically Alleviates Dopaminergic Neuronal Death in Parkinson's Disease via m6A-Dependent Regulation of ATM mRNA,” Journal of Translational Medicine 21, no. 1 (2023): 652.

[193] L. Yao, P. Peng, T. Ding, J. Yi, and J. Liang, “m6A-Induced lncRNA MEG3 Promotes Cerebral Ischemia-Reperfusion Injury via Modulating Oxidative Stress and Mitochondrial Dysfunction by hnRNPA1/Sirt2 Axis,” Molecular Neurobiology 61, no. 9 (2024): 6909.

[194] X. Zhao, C. Ma, Q. Sun, et al., “Mettl3 Regulates the Pathogenesis of Alzheimer's Disease via Fine-Tuning Lingo2,” Molecular Psychiatry 30, no. 9 (2025): 4047–4063.

[195] D. Zou, X. Huang, Y. Lan, et al., “Single-Cell and Spatial Transcriptomics Reveals That PTPRG Activates the M(6)A Methyltransferase VIRMA to Block Mitophagy-Mediated Neuronal Death in Alzheimer's Disease,” Pharmacological Research 201 (2024): 107098.

[196] P. Yang, Y. Wang, W. Ge, et al., “m6A Methyltransferase METTL3 Contributes to Sympathetic Hyperactivity Post-MI via Promoting TRAF6-Dependent Mitochondrial ROS Production,” Free Radical Biology and Medicine 209, no. Pt 2 (2023): 342–354.

[197] M. Kahl, Z. Xu, S. Arumugam, et al., “m6A RNA Methylation Regulates Mitochondrial Function,” Human Molecular Genetics 33, no. 11 (2024): 969–980.

[198] S. Liu, J. Xiu, C. Zhu, et al., “Fat Mass and Obesity-Associated Protein Regulates RNA Methylation Associated With Depression-Like Behavior in Mice,” Nature Communications 12, no. 1 (2021): 6937.

[199] J. Luo, T. Xu, and K. Sun, “N6-Methyladenosine RNA Modification in Inflammation: Roles, Mechanisms, and Applications,” Frontiers in Cell and Developmental Biology 9 (2021): 670711.

[200] X. Zhang, X. Li, H. Jia, G. An, and J. Ni, “The M(6)A Methyltransferase METTL3 Modifies PGC-1α mRNA Promoting Mitochondrial Dysfunction and oxLDL-Induced Inflammation in Monocytes,” Journal of Biological Chemistry 297, no. 3 (2021): 101058.

[201] L. Zheng, X. Chen, Q. Yin, et al., “RNA-m6A Modification of HDGF Mediated by Mettl3 Aggravates the Progression of Atherosclerosis by Regulating Macrophages Polarization via Energy Metabolism Reprogramming,” Biochemical and Biophysical Research Communications 635 (2022): 120–127.

[202] D. Wu, C. B. Spencer, L. Ortoga, H. Zhang, and C. Miao, “Histone Lactylation-Regulated METTL3 Promotes Ferroptosis via m6A-Modification on ACSL4 in Sepsis-Associated Lung Injury,” Redox Biology 74 (2024): 103194.

[203] H. Zhang, D. Wu, Y. Wang, et al., “METTL3-Mediated N6-Methyladenosine Exacerbates Ferroptosis via m6A-IGF2BP2-Dependent Mitochondrial Metabolic Reprogramming in Sepsis-Induced Acute Lung Injury,” Clinical and Translational Medicine 13, no. 9 (2023): e1389.

[204] W. Xin, J. Zhou, Y. Peng, et al., “SREBP1c-Mediated Transcriptional Repression of YME1L1 Contributes to Acute Kidney Injury by Inducing Mitochondrial Dysfunction in Tubular Epithelial Cells,” Advanced Science (Weinheim) 12, no. 6 (2025): e2412233.

[205] C. Hu, B. Zhang, and S. Zhao, “METTL3-Mediated N6-Methyladenosine Modification Stimulates Mitochondrial Damage and Ferroptosis of Kidney Tubular Epithelial Cells Following Acute Kidney Injury by Modulating the Stabilization of MDM2-p53-LMNB1 Axis,” European Journal of Medicinal Chemistry 259 (2023): 115677.

[206] F. Huang, Y. Wang, X. Lv, and C. Huang, “WTAP-Mediated N6-Methyladenosine Modification Promotes the Inflammation, Mitochondrial Damage and Ferroptosis of Kidney Tubular Epithelial Cells in Acute Kidney Injury by Regulating LMNB1 Expression and Activating NF-κB and JAK2/STAT3 Pathways,” Journal of Bioenergetics and Biomembranes 56, no. 3 (2024): 285–296.

[207] M. Y. Ke, Y. Fang, H. Cai, et al., “The m(6)A Reader YTHDF1 Attenuates Fulminant Hepatitis via MFG-E8 Translation in an m(6)A Dependent Manner,” International Journal of Biological Sciences 19, no. 12 (2023): 3987–4003.

[208] W. Zhu, W. Zhu, S. Wang, S. Liu, and H. Zhang, “UCHL1 Deficiency Upon HCMV Infection Induces Vascular Endothelial Inflammatory Injury Mediated by Mitochondrial Iron Overload,” Free Radical Biology and Medicine 211 (2024): 96–113.

[209] W. Zhu, H. Zhang, and S. Wang, “Vitamin D3 Suppresses Human Cytomegalovirus-Induced Vascular Endothelial Apoptosis via Rectification of Paradoxical m6A Modification of Mitochondrial Calcium Uniporter mRNA, Which Is Regulated by METTL3 and YTHDF3,” Frontiers in Microbiology 13 (2022): 861734.

[210] B. Song, Y. Zeng, Y. Cao, et al., “Emerging Role of METTL3 in Inflammatory Diseases: Mechanisms and Therapeutic Applications,” Frontiers in Immunology 14 (2023): 1221609.

[211] Q. Zeng, L. Li, X. Li, et al., “The M(6)A Demethylase FTO Links TLR7 to Mitochondrial Oxidation Driving Age-Associated B Cell Formation in Systemic Lupus Erythematosus,” Science Translational Medicine 17, no. 823 (2025): eadu6015.

[212] Y. Liu, X. Wang, M. Huang, et al., “METTL3 facilitates Kidney Injury Through Promoting IRF4-Mediated Plasma Cell Infiltration via an m6A-Dependent Manner in Systemic Lupus Erythematosus,” BMC Medicine [Electronic Resource] 22, no. 1 (2024): 511.

[213] Y. Zhang, Y. Zhen, Z. Ma, et al., “ALKBH3-AS1 Drives SMAD3 Stabilization via YTHDF2: Uncovering a Pathogenic Pathway for Th17 Dysregulation in SLE,” Pharmacological Research 221 (2025): 107991.

[214] Y. Xu, W. Liu, Z. Zai, et al., “METTL3 Increases Ferroptosis Resistance to Facilitate the Tumor-Like Features of Rheumatoid Arthritis Synovial Fibroblasts Through Enhancing SLC7A11 mRNA Stability in an m6A-IGF2BP2-Dependent Manner,” International Journal of Biological Macromolecules 320, no. Pt 1 (2025): 145698.

[215] Q. Geng, Y. Jiao, W. Diao, et al., “IGF2BP3-Mediated M(6)A Modification of RASGRF1 Promoting Joint Injury in Rheumatoid Arthritis,” Bone Research 13, no. 1 (2025): 51.

[216] N. Feng, C. Liu, Y. Zhu, et al., “piENOX2 Regulates ALKBH5-Mediated Itga4 M(6)A Modification to Accelerate the Progression of Rheumatoid Arthritis,” Experimental & Molecular Medicine 57, no. 7 (2025): 1579–1592.

[217] J. Tang, Z. Yu, J. Xia, et al., “METTL14-Mediated m6A Modification of TNFAIP3 Involved in Inflammation in Patients with Active Rheumatoid Arthritis,” Arthritis & Rheumatology (Hoboken, NJ) 75, no. 12 (2023): 2116–2129.

[218] E. A. Bayraktar and M. Salvatore, “The Intersection of Liver Cirrhosis and Pulmonary Fibrosis,” Journal of Translational Medicine 24, no. 1 (2025): 223.

[219] M. Zhao, L. Wang, M. Wang, et al., “Targeting Fibrosis, Mechanisms and Cilinical Trials,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 206.

[220] J. He, I. Ferapontova, J. Chen, et al., “The Immunopathophysiology of Organ Fibrosis: From Mechanisms to Immunotherapies,” Physiology (Bethesda) 40, no. 6 (2025): 0.

[221] J. Wang, Y. Yang, F. Sun, et al., “ALKBH5 attenuates Mitochondrial Fission and Ameliorates Liver Fibrosis by Reducing Drp1 Methylation,” Pharmacological Research 187 (2023): 106608.

[222] L. Chen, S. Xia, F. Wang, et al., “m(6)A Methylation-Induced NR1D1 Ablation Disrupts the HSC Circadian Clock and Promotes Hepatic Fibrosis,” Pharmacological Research 189 (2023): 106704.

[223] R. Sun, X. Tian, Y. Li, et al., “The m6A Reader YTHDF3-Mediated PRDX3 Translation Alleviates Liver Fibrosis,” Redox Biology 54 (2022): 102378.

[224] B. Tu, K. Song, Y. Zhou, et al., “METTL3 Boosts Mitochondrial Fission and Induces Cardiac Fibrosis by Enhancing LncRNA GAS5 Methylation,” Pharmacological Research 194 (2023): 106840.

[225] K. Song, H. Sun, B. Tu, et al., “WTAP Boosts Lipid Oxidation and Induces Diabetic Cardiac Fibrosis by Enhancing AR Methylation,” Iscience 26, no. 10 (2023): 107931.

[226] B. Huang, L. Xie, M. Ke, et al., “Programmed Release METTL3-14 Inhibitor Microneedle Protects Myocardial Function by Reducing Drp1 m6A Modification-Mediated Mitochondrial Fission,” ACS Applied Materials & Interfaces 15, no. 40 (2023): 46583–46597.

[227] T. T. Ensfelder, M. Q. Kurz, K. Iwan, et al., “ALKBH5-Induced Demethylation of Mono- and Dimethylated Adenosine,” Chemical Communications (Camb) 54, no. 62 (2018): 8591–8593.

[228] F. Yu, J. Wei, X. Cui, et al., “Post-Translational Modification of RNA m6A Demethylase ALKBH5 Regulates ROS-Induced DNA Damage Response,” Nucleic Acids Research 49, no. 10 (2021): 5779–5797.

[229] S. R. Li, N. N. Kang, R. R. Wang, et al., “ALKBH5 SUMOylation-Mediated FBXW7 m6A Modification Regulates Alveolar Cells Senescence During 1-Nitropyrene-Induced Pulmonary Fibrosis,” Journal of Hazardous Materials 468 (2024): 133704.

[230] Y. Long, D. Song, L. Xiao, et al., “m(6)A RNA Methylation Drives Kidney Fibrosis by Upregulating β-Catenin Signaling,” International Journal of Biological Sciences 20, no. 8 (2024): 3185–3200.

[231] H. R. Jung, J. Lee, S. P. Hong, et al., “Targeting the M(6)A RNA Methyltransferase METTL3 Attenuates the Development of Kidney Fibrosis,” Experimental & Molecular Medicine 56, no. 2 (2024): 355–369.

[232] X. He, B. Tang, P. Zou, et al., “m6A RNA Methylation: The Latent String-Puller in Fibrosis,” Life Sciences 346 (2024): 122644.

[233] X. Liu, Z. Chen, J. Lin, et al., “DLGAP5 Promotes Acute Liver Injury via Hepatocyte Pyroptosis-Driven Macrophage Metabolic Reprogramming and M1 Polarization,” International Journal of Biological Sciences 21, no. 12 (2025): 5563–5585.

[234] H. Li, K. Yu, X. Zhang, et al., “YTHDF1 Shapes Immune-Mediated Hepatitis via Regulating Inflammatory Cell Recruitment and Response,” Genes Diseases 12, no. 3 (2025): 101327.

[235] R. F. Gao, K. Yang, Y. N. Qu, et al., “m(6)A Demethylase ALKBH5 Attenuates Doxorubicin-Induced Cardiotoxicity via Posttranscriptional Stabilization of Rasal3,” Iscience 26, no. 3 (2023): 106215.

[236] Y. Cui, P. Wang, M. Li, et al., “Cinnamic Acid Mitigates Left Ventricular Hypertrophy and Heart Failure in Part Through Modulating FTO-Dependent N(6)-Methyladenosine RNA Modification in Cardiomyocytes,” Biomedicine & Pharmacotherapy 165 (2023): 115168.

[237] P. Qi, W. Zhang, Y. Gao, et al., “N6-Methyladenosine Demethyltransferase FTO Alleviates Sepsis by Upregulating BNIP3 to Induce Mitophagy,” Journal of Cellular Physiology 239, no. 12 (2024): e31448.

[238] X. Cai, P. Zou, L. Hong, et al., “RNA Methylation Reading Protein YTHDF2 Relieves Myocardial Ischemia-Reperfusion Injury by Downregulating BNIP3 via M(6)A Modification,” Human Cell 36, no. 6 (2023): 1948–1964.

[239] P. Yu, J. Wang, G. E. Xu, et al., “RNA M(6)A-Regulated Circ-ZNF609 Suppression Ameliorates Doxorubicin-Induced Cardiotoxicity by Upregulating FTO,” JACC: Basic to Translational Science 8, no. 6 (2023): 677–698.

[240] J. R. Sayers and P. R. Riley, “Heart Regeneration: Beyond New Muscle and Vessels,” Cardiovascular Research 117, no. 3 (2021): 727–742.

[241] L. E. Dorn, L. Lasman, J. Chen, et al., “The N(6)-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy,” Circulation 139, no. 4 (2019): 533–545.

[242] C. P. Rabolli, I. S. Naarmann-de Vries, C. A. Makarewich, K. K. Baskin, C. Dieterich, and F. Accornero, “Nanopore Detection of METTL3-Dependent m6A-Modified mRNA Reveals a New Mechanism Regulating Cardiomyocyte Mitochondrial Metabolism,” Circulation 149, no. 16 (2024): 1319–1322.

[243] F. Q. Jiang, K. Liu, J. X. Chen, et al., “Mettl3-mediated M(6)A Modification of Fgf16 Restricts Cardiomyocyte Proliferation During Heart Regeneration,” Elife 11 (2022): e77014.

[244] P. Sun, C. Wang, G. Mang, et al., “Extracellular Vesicle-Packaged Mitochondrial Disturbing miRNA Exacerbates Cardiac Injury During Acute Myocardial Infarction,” Clinical and Translational Medicine 12, no. 4 (2022): e779.

[245] L. Liu, J. Wu, C. Lu, et al., “WTAP-Mediated M(6)A Modification of lncRNA Snhg1 Improves Myocardial Ischemia-Reperfusion Injury via miR-361-5p/OPA1-Dependent Mitochondrial Fusion,” Journal of Translational Medicine 22, no. 1 (2024): 499.

[246] S. Luo, Q. Zhang, W. Zhou, et al., “METTL3 Promotes Neutrophil Extracellular Trap Formation via SYK/ERK/MEK Signaling During Acute Lung Injury,” Journal of Advanced Research (2026).

[247] A. Sang, J. Zhang, M. Zhang, et al., “METTL4 mediated-N6-Methyladenosine Promotes Acute Lung Injury by Activating Ferroptosis in Alveolar Epithelial Cells,” Free Radical Biology and Medicine 213 (2024): 90–101.

[248] F. Cao, G. Chen, Y. Xu, et al., “METTL14 Contributes to Acute Lung Injury by Stabilizing NLRP3 Expression in an IGF2BP2-Dependent Manner,” Cell Death & Disease 15, no. 1 (2024): 43.

[249] S. Wu, W. Tang, L. Liu, et al., “Obesity-Induced Downregulation of miR-192 Exacerbates Lipopolysaccharide-Induced Acute Lung Injury by Promoting Macrophage Activation,” Cellular & Molecular Biology Letters 29, no. 1 (2024): 36.

[250] X. G. Suo, J. N. Wang, Q. Zhu, et al., “METTL3 mediated m6A Modification of HKDC1 Promotes Renal Injury and Inflammation in Lead Nephropathy,” International Journal of Biological Sciences 21, no. 8 (2025): 3755–3775.

[251] M. L. Ji, L. J. Peng, Q. Zhu, et al., “METTL3-Mediated m6A Modification of TIFA mRNA Promotes Tubular Cell Pyroptosis in Acute Kidney Injury,” Free Radical Biology and Medicine 244 (2026): 68–83.

[252] L. Lv, M. Hu, J. Li, et al., “Methyltransferase-Like 3 Mediates m6A Modification of Heme Oxygenase 1 mRNA to Induce Ferroptosis of Renal Tubular Epithelial Cells in Acute Kidney Injury,” Free Radical Biology and Medicine 229 (2025): 168–182.

[253] T. Ma, Y. Yu, H. Luo, et al., “CircAASS Alleviates Renal Injury and Fibrosis by Regulating Mitochondrial Homeostasis in Tubular Epithelial Cells,” Autophagy 22, no. 1 (2026): 182–206.

[254] W. Yang, M. Zhang, J. Li, et al., “YTHDF1 Mitigates Acute Kidney Injury via Safeguarding M(6)A-Methylated mRNAs in Stress Granules of Renal Tubules,” Redox Biology 67 (2023): 102921.

[255] P. J. Fernandez-Marcos and J. Auwerx, “Regulation of PGC-1α, a Nodal Regulator of Mitochondrial Biogenesis,” American Journal of Clinical Nutrition 93, no. 4 (2011): 884s–890.

[256] L. Wu, L. Wang, Y. Du, Y. Zhang, and J. Ren, “Mitochondrial Quality Control Mechanisms as Therapeutic Targets in Doxorubicin-Induced Cardiotoxicity,” Trends in Pharmacological Sciences 44, no. 1 (2023): 34–49.

[257] L. D. Popov, “Mitochondrial Biogenesis: An Update,” Journal of Cellular and Molecular Medicine 24, no. 9 (2020): 4892–4899.

[258] C. Zhuang, C. Zhuang, X. Luo, et al., “N6-methyladenosine Demethylase FTO Suppresses Clear Cell Renal Cell Carcinoma Through a Novel FTO-PGC-1α Signalling Axis,” Journal of Cellular and Molecular Medicine 23, no. 3 (2019): 2163–2173.

[259] K. Deng, Y. Fan, Y. Liang, et al., “FTO-Mediated Demethylation of GADD45B Promotes Myogenesis Through the Activation of p38 MAPK Pathway,” Molecular Therapy Nucleic Acids 26 (2021): 34–48.

[260] W. Chen, Y. Chen, R. Wu, et al., “DHA Alleviates Diet-Induced Skeletal Muscle fiber Remodeling via FTO/M(6)A/DDIT4/PGC1α Signaling,” BMC Biology 20, no. 1 (2022): 39.

[261] C. Zhao, B. Hu, Z. Wang, et al., “METTL3-Dependent M(6)A Modification of GHR mRNA Regulates Mitochondrial Function Through Mitochondrial Biogenesis During Myoblast Differentiation,” Poultry Science 104, no. 7 (2025): 105216.

[262] E. Balsa, R. Marco, E. Perales-Clemente, et al., “NDUFA4 is a Subunit of Complex IV of the Mammalian Electron Transport Chain,” Cell Metabolism 16, no. 3 (2012): 378–386.

[263] W. Xu, Y. Lai, Y. Pan, et al., “m6A RNA Methylation-Mediated NDUFA4 Promotes Cell Proliferation and Metabolism in Gastric Cancer,” Cell Death & Disease 13, no. 8 (2022): 715.

[264] Y. Yan, A. Luo, S. Liu, et al., “METTL3-Mediated LINC00475 Alternative Splicing Promotes Glioma Progression by Inducing Mitochondrial Fission,” Research (Washington, DC) 7 (2024): 0324.

[265] Y. Zhou, Q. Wang, H. Deng, et al., “N6-Methyladenosine Demethylase FTO Promotes Growth and Metastasis of Gastric Cancer via M(6)A Modification of Caveolin-1 and Metabolic Regulation of Mitochondrial Dynamics,” Cell Death & Disease 13, no. 1 (2022): 72.

[266] Z. Y. Liu, L. C. Lin, Z. Y. Liu, et al., “N(6)-Methyladenosine-Mediated Phase Separation Suppresses NOTCH1 Expression and Promotes Mitochondrial Fission in Diabetic Cardiac Fibrosis,” Cardiovascular Diabetology 23, no. 1 (2024): 347.

[267] D. Yuan, H. Li, W. Dai, X. Zhou, W. Zhou, and L. He, “IGF2BP3-Stabilized CAMK1 Regulates the Mitochondrial Dynamics of Renal Tubule to Alleviate Diabetic Nephropathy,” Biochimica Et Biophysica Acta, Molecular Basis of Disease 1870, no. 3 (2024): 167022.

[268] Z. Zhang, F. Zhou, M. Lu, et al., “WTAP-Mediated M(6)A Modification of TRIM22 Promotes Diabetic Nephropathy by Inducing Mitochondrial Dysfunction via Ubiquitination of OPA1,” Redox Report: Communications in Free Radical Research 29, no. 1 (2024): 2404794.

[269] K. Sun, L. Chen, Y. Li, et al., “METTL14-Dependent Maturation of Pri-miR-17 Regulates Mitochondrial Homeostasis and Induces Chemoresistance in Colorectal Cancer,” Cell Death & Disease 14, no. 2 (2023): 148.

[270] J. Zhou, H. Zhang, K. Zhong, et al., “N6-Methyladenosine Facilitates Mitochondrial Fusion of Colorectal Cancer Cells via Induction of GSH Synthesis and Stabilization of OPA1 mRNA,” National Science Review 11, no. 3 (2024): nwae039.

[271] Y. Sun, W. Shen, S. Hu, et al., “METTL3 Promotes Chemoresistance in Small Cell Lung Cancer by Inducing Mitophagy,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 65.

[272] F. Wang, J. Bai, X. Zhang, et al., “METTL3/YTHDF2 m6A axis Mediates the Progression of Diabetic Nephropathy Through Epigenetically Suppressing PINK1 and Mitophagy,” Journal of Diabetes Investigation 15, no. 3 (2024): 288–299.

[273] X. Deng, X. Sun, Z. Hu, et al., “Exploring the Role of m6A Methylation Regulators in Glioblastoma Multiforme and Their Impact on the Tumor Immune Microenvironment,” Faseb Journal 37, no. 9 (2023): e23155.

[274] L. Guowei, L. Xiufang, X. Qianqian, and J. Yanping, “The FDX1 Methylation Regulatory Mechanism in the Malignant Phenotype of Glioma,” Genomics 115, no. 2 (2023): 110601.

[275] H. Pei, Y. Dai, Y. Yu, et al., “The Tumorigenic Effect of lncRNA AFAP1-AS1 Is Mediated by Translated Peptide ATMLP under the Control of M(6) A Methylation,” Advanced Science (Weinheim) 10, no. 13 (2023): e2300314.

[276] J. Song, Y. Chen, Y. Chen, et al., “DKK3 Promotes Renal Fibrosis by Increasing MFF-Mediated Mitochondrial Dysfunction in Wnt/β-Catenin Pathway-Dependent Manner,” Renal Failure 46, no. 1 (2024): 2343817.

[277] H. Chen, H. Xing, C. Zhong, et al., “METTL3 Confers Protection Against Mitochondrial Dysfunction and Cognitive Impairment in an Alzheimer Disease Mouse Model by Upregulating Mfn2 via N6-Methyladenosine Modification,” Journal of Neuropathology and Experimental Neurology 83, no. 7 (2024): 606–614.

[278] W. Wang, X. Ma, S. Bhatta, et al., “Intraneuronal β-Amyloid Impaired Mitochondrial Proteostasis Through the Impact on LONP1,” PNAS 120, no. 51 (2023): e2316823120.

[279] J. Du, R. Sarkar, Y. Li, et al., “N(6)-Adenomethylation of GsdmC Is Essential for Lgr5(+) Stem Cell Survival to Maintain Normal Colonic Epithelial Morphogenesis,” Developmental Cell 57, no. 16 (2022): 1976–1994.e8.

[280] W. Wang, J. Yan, L. Han, Z. L. Zou, and A. L. Xu, “Silencing METTL14 Alleviates Liver Injury in Non-Alcoholic Fatty Liver Disease by Regulating Mitochondrial Homeostasis,” Biomolecules & Biomedicine 24, no. 3 (2024): 505–519.

[281] J. Jin, Y. Shang, S. Zheng, et al., “Exosomes as Nanostructures Deliver miR-204 in Alleviation of Mitochondrial Dysfunction in Diabetic Nephropathy Through Suppressing Methyltransferase-Like 7A-Mediated CIDEC N6-Methyladenosine Methylation,” Aging 16, no. 4 (2024): 3302–3331.

[282] Y. Jiao, S. Wang, X. Wang, et al., “The m(6)A Reader YTHDC2 Promotes SIRT3 Expression by Reducing the Stabilization of KDM5B to Improve Mitochondrial Metabolic Reprogramming in Diabetic Peripheral Neuropathy,” Acta Diabetologica 60, no. 3 (2023): 387–399.

[283] W. Yan, L. I. K. Saqirile, K. Li, and C. Wang, “The Role of N6-Methyladenosine in Mitochondrial Dysfunction and Pathology,” International Journal of Molecular Sciences 26, no. 8 (2025): 3624.

[284] D. Tews, P. Fischer-Posovszky, T. Fromme, et al., “FTO Deficiency Induces UCP-1 Expression and Mitochondrial Uncoupling in Adipocytes,” Endocrinology 154, no. 9 (2013): 3141–3151.

[285] R. Wu, Y. Chen, Y. Liu, et al., “m6A methylation Promotes White-to-Beige Fat Transition by Facilitating Hif1a Translation,” Embo Reports 22, no. 11 (2021): e52348.

[286] Z. Shen, P. Liu, Q. Sun, et al., “FTO Inhibits UPR(mt)-Induced Apoptosis by Activating JAK2/STAT3 Pathway and Reducing m6A Level in Adipocytes,” Apoptosis 26, no. 7-8 (2021): 474–487.

[287] D. Wei, Q. Sun, Y. Li, C. Li, X. Li, and C. Sun, “Leptin Reduces Plin5 M(6)A Methylation Through FTO to Regulate Lipolysis in Piglets,” International Journal of Molecular Sciences 22, no. 19 (2021): 10610.

[288] R. Xie, S. Yan, X. Zhou, et al., “Activation of METTL3 Promotes White Adipose Tissue Beiging and Combats Obesity,” Diabetes 72, no. 8 (2023): 1083–1094.

[289] S. Yan, X. Zhou, C. Wu, et al., “Adipocyte YTH N(6)-Methyladenosine RNA-Binding Protein 1 Protects Against Obesity by Promoting White Adipose Tissue Beiging in Male Mice,” Nature Communications 14, no. 1 (2023): 1379.

[290] J. Yuan, B. M. Xie, Y. M. Ji, et al., “piR-26441 Inhibits Mitochondrial Oxidative Phosphorylation and Tumorigenesis in Ovarian Cancer Through m6A Modification by Interacting With YTHDC1,” Cell Death & Disease 16, no. 1 (2025): 25.

[291] B. Tu, K. Song, Z. Y. Zhou, et al., “SLC31A1 Loss Depletes Mitochondrial Copper and Promotes Cardiac Fibrosis,” European Heart Journal 46, no. 25 (2025): 2458–2474.

[292] E. Yankova, W. Blackaby, M. Albertella, et al., “Small-Molecule Inhibition of METTL3 as a Strategy Against Myeloid Leukaemia,” Nature 593, no. 7860 (2021): 597–601.

[293] Q. Liu, J. Qi, W. Li, et al., “Therapeutic Effect and Transcriptome-Methylome Characteristics of METTL3 Inhibition in Liver Hepatocellular Carcinoma,” Cancer Cell International 23, no. 1 (2023): 298.

[294] S. Wang, Y. Zeng, L. Zhu, et al., “The N6-Methyladenosine Epitranscriptomic Landscape of Lung Adenocarcinoma,” Cancer Discovery 14, no. 11 (2024): 2279–2299.

[295] Y. Yu, Y. Hai, H. Zhou, et al., “METTL3 Inhibition Suppresses Cell Growth and Survival in Colorectal Cancer via ASNS Downregulation,” Journal of Cancer 15, no. 15 (2024): 4853–4865.

[296] Z. Li, X. Zhang, C. Liu, et al., “Engineering a Nano-Drug Delivery System to Regulate m6A Modification and Enhance Immunotherapy in Gastric Cancer,” Acta Biomaterialia 191 (2025): 412–427.

[297] G. Shan, W. Wang, X. Li, et al., “Epigenetic-Targeted Biomimetic Nanomedicine Modulates Epithelial Mesenchymal Transition to Enhance Chemosensitivity in Heterogeneous Tumors,” Biomaterials 324 (2026): 123529.

[298] J. Li, L. Wei, K. Hu, et al., “Deciphering m(6)A Methylation in Monocyte-Mediated Cardiac Fibrosis and Monocyte-Hitchhiked Erythrocyte Microvesicle Biohybrid Therapy,” Theranostics 14, no. 9 (2024): 3486–3508.

[299] J. Li and R. I. Gregory, “Mining for METTL3 Inhibitors to Suppress Cancer,” Nature Structural & Molecular Biology 28, no. 6 (2021): 460–462.

[300] G. Dutheuil, K. Oukoloff, J. Korac, et al., “Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor With Efficacy in Liquid and Solid Tumor Models,” Journal of Medicinal Chemistry 68, no. 3 (2025): 2981–3003.

[301] F. Errani, A. Invernizzi, M. Herok, et al., “Proteolysis Targeting Chimera Degraders of the METTL3-14 M(6)A-RNA Methyltransferase,” JACS Au 4, no. 2 (2024): 713–729.

[302] E. V. Moroz-Omori, D. Huang, R. Kumar Bedi, et al., “METTL3 Inhibitors for Epitranscriptomic Modulation of Cellular Processes,” Chemmedchem 16, no. 19 (2021): 3035–3043.

[303] Y. Yanagi, T. Watanabe, Y. Hara, Y. Sato, H. Kimura, and T. Murata, “EBV Exploits RNA M(6)A Modification to Promote Cell Survival and Progeny Virus Production during Lytic Cycle,” Frontiers in Microbiology 13 (2022): 870816.

[304] X. Zhou, X. Yang, S. Huang, et al., “Inhibition of METTL3 Alleviates NLRP3 Inflammasome Activation via Increasing Ubiquitination of NEK7,” Advanced science (Weinheim) 11, no. 26 (2024): e2308786.

[305] R. K. Bedi, D. Huang, Y. Li, and A. Caflisch, “Structure-Based Design of Inhibitors of the M(6)A-RNA Writer Enzyme METTL3,” ACS Bio & Med Chem Au 3, no. 4 (2023): 359–370.

[306] A. Dolbois, R. K. Bedi, E. Bochenkova, et al., “1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors,” Journal of Medicinal Chemistry 64, no. 17 (2021): 12738–12760.

[307] Y. Du, Y. Yuan, L. Xu, et al., “Discovery of METTL3 Small Molecule Inhibitors by Virtual Screening of Natural Products,” Frontiers in Pharmacology 13 (2022): 878135.

[308] L. Li, Q. Chai, C. Guo, et al., “METTL3-Mediated N6-Methyladenosine Modification Contributes to Vascular Calcification,” Journal of Molecular and Cellular Cardiology 203 (2025): 22–34.

[309] L. Zhao, H. Ma, Y. Jiang, et al., “Identification of an m6A Natural Inhibitor, Lobeline, That Reverses Lenvatinib Resistance in Hepatocellular Tumors,” Journal of Natural Products 87, no. 8 (2024): 1983–1993.

[310] J. Yang, Y. He, Y. Kang, et al., “Virtual Screening and Molecular Docking: Discovering Novel METTL3 Inhibitors,” ACS Medicinal Chemistry Letters 15, no. 9 (2024): 1491–1499.

[311] H. Yin, Z. Ju, X. Zhang, et al., “Inhibition of METTL3 in Macrophages Provides Protection Against Intestinal Inflammation,” Cellular & Molecular Immunology 21, no. 6 (2024): 589–603.

[312] C. Liu, D. Fan, and J. Sun, “Inhibition of METTL14 Overcomes CDK4/6 Inhibitor Resistance Driven by METTL14-m6A-E2F1-Axis in ERα-Positive Breast Cancer,” J Nanobiotechnology 23, no. 1 (2025): 3.

[313] J. H. Lee, S. Kim, M. S. Jin, and Y. C. Kim, “Discovery of Substituted Indole Derivatives as Allosteric Inhibitors of M(6) A-RNA Methyltransferase, METTL3-14 Complex,” Drug Development Research 83, no. 3 (2022): 783–799.

[314] J. H. Lee, N. Choi, S. Kim, M. S. Jin, H. Shen, and Y. C. Kim, “Eltrombopag as an Allosteric Inhibitor of the METTL3-14 Complex Affecting the M(6)A Methylation of RNA in Acute Myeloid Leukemia Cells,” Pharmaceuticals (Basel, Switzerland) 15, no. 4 (2022): 440.

[315] Y. Liu, G. L. Goebel, L. Kanis, O. Hastürk, C. Kemker, and P. Wu, “Aminothiazolone Inhibitors Disrupt the Protein-RNA Interaction of METTL16 and Modulate the M(6)A RNA Modification,” JACS Au 4, no. 4 (2024): 1436–1449.

[316] inventors; City of Hope, assignee J. Chen, X. Deng, L. Han, H. Li, and R. Su, “Methyltransferase-Like Protein 16 (METTL16) Inhibitors and Uses Thereof for Treating Cancer. Patent WO2021035045,” in patent application Copyright © 2025 American Chemical Society (ACS). All Rights Reserved (2021).

[317] B. Chen, F. Ye, L. Yu, et al., “Development of Cell-Active N6-Methyladenosine RNA Demethylase FTO Inhibitor,” Journal of the American Chemical Society 134, no. 43 (2012): 17963–17971.

[318] Y. Niu, Z. Lin, A. Wan, et al., “RNA N6-Methyladenosine Demethylase FTO Promotes Breast Tumor Progression Through Inhibiting BNIP3,” Molecular Cancer 18, no. 1 (2019): 46.

[319] F. Yan, A. Al-Kali, Z. Zhang, et al., “A Dynamic N(6)-Methyladenosine Methylome Regulates Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors,” Cell Research 28, no. 11 (2018): 1062–1076.

[320] Y. Zhuang, Y. Bai, Y. Hu, et al., “Rhein Sensitizes human Colorectal Cancer Cells to EGFR Inhibitors by Inhibiting STAT3 Pathway,” OncoTargets and Therapy 12 (2019): 5281–5291.

[321] Y. Qiao, M. Su, H. Zhao, et al., “Targeting FTO Induces Colorectal Cancer Ferroptotic Cell Death by Decreasing SLC7A11/GPX4 Expression,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 108.

[322] K. Sun, Y. Du, Y. Hou, et al., “Saikosaponin D Exhibits Anti-Leukemic Activity by Targeting FTO/M(6)A Signaling,” Theranostics 11, no. 12 (2021): 5831–5846.

[323] Y. Huang, J. Yan, Q. Li, et al., “Meclofenamic Acid Selectively Inhibits FTO Demethylation of m6A Over ALKBH5,” Nucleic Acids Research 43, no. 1 (2015): 373–384.

[324] H. Chen, B. Jia, Q. Zhang, and Y. Zhang, “Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 via FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer,” Frontiers in Oncology 12 (2022): 870636.

[325] Q. Cui, H. Shi, P. Ye, et al., “m(6)A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells,” Cell Reports 18, no. 11 (2017): 2622–2634.

[326] L. Xiao, X. Li, Z. Mu, et al., “FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma,” Cancer Research 80, no. 18 (2020): 3945–3958.

[327] Y. Zhang, Q. N. Li, K. Zhou, Q. Xu, and C. Y. Zhang, “Identification of Specific N(6)-Methyladenosine RNA Demethylase FTO Inhibitors by Single-Quantum-Dot-Based FRET Nanosensors,” Analytical Chemistry 92, no. 20 (2020): 13936–13944.

[328] S. Peng, W. Xiao, and D. Ju, “Identification of Entacapone as a Chemical Inhibitor of FTO Mediating Metabolic Regulation Through FOXO1,” Science Translational Medicine 11, no. 488 (2019): eaau7116.

[329] R. Su, L. Dong, Y. Li, et al., “Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion,” Cancer Cell 38, no. 1 (2020): 79–96.e11.

[330] G. Zheng, T. Cox, L. Tribbey, et al., “Synthesis of a FTO Inhibitor With Anticonvulsant Activity,” Acs Chemical Neuroscience 5, no. 8 (2014): 658–665.

[331] B. Singh, H. E. Kinne, R. D. Milligan, L. J. Washburn, M. Olsen, and A. Lucci, “Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge,” PLoS ONE 11, no. 7 (2016): e0159072.

[332] R. Su, L. Dong, C. Li, et al., “R-2HG Exhibits Anti-Tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling,” Cell 172, no. 1-2 (2018): 90–105.e23.

[333] Y. Huang, R. Su, Y. Sheng, et al., “Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia,” Cancer Cell 35, no. 4 (2019): 677–691.e10.

[334] Z. Lian, R. Chen, M. Xian, et al., “Targeted Inhibition of m6A Demethylase FTO by FB23 Attenuates Allergic Inflammation in the Airway Epithelium,” Faseb Journal 38, no. 15 (2024): e23846.

[335] Y. Xu, J. Zhou, L. Li, et al., “FTO-mediated Autophagy Promotes Progression of Clear Cell Renal Cell Carcinoma via Regulating SIK2 mRNA Stability,” International Journal of Biological Sciences 18, no. 15 (2022): 5943–5962.

[336] Z. Xiao, T. Li, X. Zheng, et al., “Nanodrug Enhances Post-Ablation Immunotherapy of Hepatocellular Carcinoma via Promoting Dendritic Cell Maturation and Antigen Presentation,” Bioactive Materials 21 (2023): 57–68.

[337] Y. P. Yen, T. H. Lung, E. S. Liau, et al., “The Motor Neuron m6A Repertoire Governs Neuronal Homeostasis and FTO Inhibition Mitigates ALS Symptom Manifestation,” Nature Communications 16, no. 1 (2025): 4063.

[338] X. Zheng, S. Deng, Y. Li, et al., “Targeting M(6)A Demethylase FTO to Heal Diabetic Wounds With ROS-Scavenging Nanocolloidal Hydrogels,” Biomaterials 317 (2025): 123065.

[339] Z. Liu, Z. Duan, D. Zhang, et al., “Structure-Activity Relationships and Antileukemia Effects of the Tricyclic Benzoic Acid FTO Inhibitors,” Journal of Medicinal Chemistry 65, no. 15 (2022): 10638–10654.

[340] T. Yang, Z. Dong, R. Du, et al., “Development of Orally Bioavailable FTO Inhibitors With Potent Antileukemia Efficacy,” Journal of Medicinal Chemistry 68, no. 13 (2025): 13714–13727.

[341] Y. Liu, G. Liang, H. Xu, et al., “Tumors Exploit FTO-Mediated Regulation of Glycolytic Metabolism to Evade Immune Surveillance,” Cell Metabolism 33, no. 6 (2021): 1221–1233.e11.

[342] T. Wang, T. Hong, Y. Huang, et al., “Fluorescein Derivatives as Bifunctional Molecules for the Simultaneous Inhibiting and Labeling of FTO Protein,” Journal of the American Chemical Society 137, no. 43 (2015): 13736–13739.

[343] D. Zhang, L. Liu, M. Li, et al., “Development of 3-Arylaminothiophenic-2-Carboxylic Acid Derivatives as New FTO Inhibitors Showing Potent Antileukemia Activities,” European Journal of Medicinal Chemistry 289 (2025): 117444.

[344] X. Liang, Y. Huang, H. Ren, et al., “Discovery of Novel RNA Demethylase FTO Inhibitors Featuring an Acylhydrazone Scaffold With Potent Antileukemia Activity,” Journal of Medicinal Chemistry 68, no. 3 (2025): 2742–2763.

[345] B. Qin, Q. Bai, D. Yan, et al., “Discovery of Novel mRNA Demethylase FTO Inhibitors Against Esophageal Cancer,” Journal of Enzyme Inhibition and Medicinal Chemistry 37, no. 1 (2022): 1995–2003.

[346] S. Huff, S. K. Tiwari, G. M. Gonzalez, Y. Wang, and T. M. Rana, “m(6)A-RNA Demethylase FTO Inhibitors Impair Self-Renewal in Glioblastoma Stem Cells,” ACS Chemical Biology 16, no. 2 (2021): 324–333.

[347] S. Huff, I. R. Kummetha, L. Zhang, et al., “Rational Design and Optimization of M(6)A-RNA Demethylase FTO Inhibitors as Anticancer Agents,” Journal of Medicinal Chemistry 65, no. 16 (2022): 10920–10937.

[348] M. Prakash, Y. Itoh, Y. Fujiwara, et al., “Identification of Potent and Selective Inhibitors of Fat Mass Obesity-Associated Protein Using a Fragment-Merging Approach,” Journal of Medicinal Chemistry 64, no. 21 (2021): 15810–15824.

[349] G. Xie, X. N. Wu, Y. Ling, et al., “A Novel Inhibitor of N (6)-Methyladenosine Demethylase FTO Induces mRNA Methylation and Shows Anti-Cancer Activities,” Acta Pharmaceutica Sinica B 12, no. 2 (2022): 853–866.

[350] Y. Qiao, B. Zhou, M. Zhang, et al., “A Novel Inhibitor of the Obesity-Related Protein FTO,” Biochemistry 55, no. 10 (2016): 1516–1522.

[351] W. He, B. Zhou, W. Liu, et al., “Identification of a Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO),” Journal of Medicinal Chemistry 58, no. 18 (2015): 7341–7348.

[352] R. Wang, Z. Han, B. Liu, et al., “Identification of Natural Compound Radicicol as a Potent FTO Inhibitor,” Molecular Pharmaceutics 15, no. 9 (2018): 4092–4098.

[353] S. Selberg, L. Y. Yu, O. Bondarenko, et al., “Small-Molecule Inhibitors of the RNA M6A Demethylases FTO Potently Support the Survival of Dopamine Neurons,” International Journal of Molecular Sciences 22, no. 9 (2021): 4537.

[354] X. Yang, K. Huang, X. N. Wu, et al., “Discovery of a Novel Selective and Cell-Active N(6)-Methyladenosine RNA Demethylase ALKBH5 Inhibitor,” Journal of Medicinal Chemistry 68, no. 4 (2025): 4133–4147.

[355] A. Malacrida, M. Rivara, A. Di Domizio, et al., “3D Proteome-Wide Scale Screening and Activity Evaluation of a New ALKBH5 Inhibitor in U87 Glioblastoma Cell Line,” Bioorganic & Medicinal Chemistry 28, no. 4 (2020): 115300.

[356] H. Takahashi, H. Hase, T. Yoshida, et al., “Discovery of Two Novel ALKBH5 Selective Inhibitors That Exhibit Uncompetitive or Competitive Type and Suppress the Growth Activity of Glioblastoma Multiforme,” Chemical Biology and Drug Design 100, no. 1 (2022): 1–12.

[357] Y. Z. Wang, H. Y. Li, Y. Zhang, et al., “Discovery of Pyrazolo[1,5-a]Pyrimidine Derivative as a Novel and Selective ALKBH5 Inhibitor for the Treatment of AML,” Journal of Medicinal Chemistry 66, no. 23 (2023): 15944–15959.

[358] W. L. Fei, Y. Z. Wang, Q. L. Feng, et al., “Discovery of the Salicylaldehyde-Based Compound DDO-02267 as a Lysine-Targeting Covalent Inhibitor of ALKBH5,” European Journal of Medicinal Chemistry 284 (2025): 117183.

[359] L. Liang, W. Fei, Y. Wang, Z. Zhang, Q. You, and X. Guo, “Discovery of Maleimide Derivatives as M(6)A Demethylase ALKBH5 Inhibitors,” Bioorganic & Medicinal Chemistry 120 (2025): 118083.

[360] S. Selberg, N. Seli, E. Kankuri, and M. Karelson, “Rational Design of Novel Anticancer Small-Molecule RNA m6A Demethylase ALKBH5 Inhibitors,” ACS Omega 6, no. 20 (2021): 13310–13320.

[361] R. W. Sabnis, “Novel Small Molecule RNA m6A Demethylase AlkBH5 Inhibitors for Treating Cancer,” ACS Medicinal Chemistry Letters 12, no. 6 (2021): 856–857.

[362] N. Li, Y. Kang, L. Wang, et al., “ALKBH5 Regulates Anti-PD-1 Therapy Response by Modulating Lactate and Suppressive Immune Cell Accumulation in Tumor Microenvironment,” PNAS 117, no. 33 (2020): 20159–20170.

[363] Z. Fang, B. Mu, Y. Liu, et al., “Discovery of a Potent, Selective and Cell Active Inhibitor of M(6)A Demethylase ALKBH5,” European Journal of Medicinal Chemistry 238 (2022): 114446.

[364] L. G. Cui, S. H. Wang, S. Komal, et al., “ALKBH5 promotes Cardiac Fibroblasts Pyroptosis After Myocardial Infarction Through Notch1/NLRP3 Pathway,” Cell Signalling 127 (2025): 111574.

[365] W. Meng, H. Xiao, R. Zhao, et al., “METTL3 drives NSCLC Metastasis by Enhancing CYP19A1 Translation and Oestrogen Synthesis,” Cell & Bioscience 14, no. 1 (2024): 10.

[366] M. Pomaville, M. Chennakesavalu, P. Wang, et al., “Small-Molecule Inhibition of the METTL3/METTL14 Complex Suppresses Neuroblastoma Tumor Growth and Promotes Differentiation,” Cell Reports 43, no. 5 (2024): 114165.

[367] X. Sun, C. Bai, H. Li, et al., “PARP1 Modulates METTL3 Promoter Chromatin Accessibility and Associated LPAR5 RNA M(6)A Methylation to Control Cancer Cell Radiosensitivity,” Molecular Therapy 31, no. 9 (2023): 2633–2650.

[368] C. Zhang, M. Lei, and T. Mou, “inventors; Sichuan Haisco Pharmaceutical Co., Ltd., Assignee. Mettl3 Inhibitor and Composition, and Application in Medicine. Patent WO2023151697,” in patent application Copyright © 2025 American Chemical Society (ACS). All Rights Reserved (2023).

[369] X. Bai, X. Hong, and H. N. Mark, “inventors; Shanghai Oncusp Therapeutics Ltd, Assignee. Mettl3 Inhibitor Compound. Patent WO2023104209,” in patent application Copyright © 2025 American Chemical Society (ACS). All Rights Reserved (2023).

[370] D. J. Hardick, W. P. Blackaby, and E. J. Thomas, “inventors; Storm Therapeutics Limited, Assignee. Preparation of Heteroaromatic Compounds as METTL3 Inhibitory Compounds. Patent WO2022074379,” in patent application Copyright © 2025 American Chemical Society (ACS). All Rights Reserved (2022).

[371] W. P. Blackaby, D. J. Hardick, and E. J. Thomas, “inventors; Storm Therapeutics Ltd, Assignee. Preparation of Imidazopyridines and Related Derivatives as MeTTL3 Inhibitors. Patent WO2020201773,” in patent application Copyright © 2025 American Chemical Society (ACS). All Rights Reserved (2020).

[372] inventors; Hangzhou Bangshun Pharmaceutical Co., Ltd., assignee Q. Wen, X. Yang, and R. Cui, “Preparation of Pyrazolo[1,5-a]Pyrazine-based Compounds as METTL3 Inhibitors. Patent CN119899188,” in patent application Copyright © 2025 American Chemical Society (ACS). All Rights Reserved (2025).

[373] inventors; NovAliX Aqemia, assignee L. Mevellec, H. Prevet, P. Schambel, and N. George, “Preparation of Substituted N-(quinolin-6-ylmethyl) heteroarylcarboxamides as Novel METTL3 Inhibitors and Use Thereof in Therapy. Patent WO2024200835,” in patent application Copyright © 2025 American Chemical Society (ACS). All Rights Reserved (2024).

[374] R. K. Bedi, D. Huang, S. A. Eberle, L. Wiedmer, P. Śledź, and A. Caflisch, “Small-Molecule Inhibitors of METTL3, the Major Human Epitranscriptomic Writer,” Chemmedchem 15, no. 9 (2020): 744–748.

[375] M. Mannes, C. Martin, C. Menet, and S. Ballet, “Wandering Beyond Small Molecules: Peptides as Allosteric Protein Modulators,” Trends in Pharmacological Sciences 43, no. 5 (2022): 406–423.

[376] Z. Han, T. Niu, J. Chang, et al., “Crystal Structure of the FTO Protein Reveals Basis for Its Substrate Specificity,” Nature 464, no. 7292 (2010): 1205–1209.

[377] Q. Li, Y. Huang, X. Liu, J. Gan, H. Chen, and C. G. Yang, “Rhein Inhibits AlkB Repair Enzymes and Sensitizes Cells to Methylated DNA Damage,” Journal of Biological Chemistry 291, no. 21 (2016): 11083–11093.

[378] S. Zhang, L. Zhou, J. Yang, et al., “Rhein Exerts Anti-Multidrug Resistance in Acute Myeloid Leukemia via Targeting FTO to Inhibit AKT/mTOR,” Anti-Cancer Drugs 35, no. 7 (2024): 597–605.

[379] S. S. Gao, J. Hothersall, J. Wu, et al., “Biosynthesis of Mupirocin by Pseudomonas Fluorescens NCIMB 10586 Involves Parallel Pathways,” Journal of the American Chemical Society 136, no. 14 (2014): 5501–5507.

[380] X. Jiang, B. R. Stockwell, and M. Conrad, “Ferroptosis: Mechanisms, Biology and Role in Disease,” Nature Reviews Molecular Cell Biology 22, no. 4 (2021): 266–282.

[381] S. Gu, Y. Zheng, C. Chen, et al., “Research Progress on the Molecular Mechanisms of Saikosaponin D in Various Diseases (Review),” International Journal of Molecular Medicine 55, no. 3 (2025): 37.

[382] P. Caetano-Pinto, J. Jansen, Y. G. Assaraf, and R. Masereeuw, “The Importance of Breast Cancer Resistance Protein to the Kidneys Excretory Function and Chemotherapeutic Resistance,” Drug Resistance Updates 30 (2017): 15–27.

[383] R. W. Robey, K. M. Pluchino, M. D. Hall, A. T. Fojo, S. E. Bates, and M. M. Gottesman, “Revisiting the Role of ABC Transporters in Multidrug-Resistant Cancer,” Nature Reviews Cancer 18, no. 7 (2018): 452–464.

[384] P. T. Männistö, T. Keränen, K. J. Reinikainen, A. Hanttu, and P. Pollesello, “The Catechol O-Methyltransferase Inhibitor Entacapone in the Treatment of Parkinson's Disease: Personal Reflections on a First-in-Class Drug Development Programme 40 Years On,” Neurology and Therapy 13, no. 4 (2024): 1039–1054.

[385] H. Y. Yap, B. S. Yap, G. R. Blumenschein, B. C. Barnes, F. C. Schell, and G. P. Bodey, “Bisantrene, an Active New Drug in the Treatment of Metastatic Breast Cancer,” Cancer Research 43, no. 3 (1983): 1402–1404.

[386] M. de Forni, G. G. Chabot, J. P. Armand, et al., “Phase I and Pharmacokinetic Study of Brequinar (DUP 785; NSC 368390) in Cancer Patients,” European Journal of Cancer 29a, no. 7 (1993): 983–988.

[387] Z. Dong, Y. Huang, W. Xia, Y. Liao, and C. G. Yang, “A Patenting Perspective of Fat Mass and Obesity Associated Protein (FTO) Inhibitors: 2017-Present,” Expert Opinion on Therapeutic Patents 35, no. 6 (2025): 533–542.

[388] W. Aik, M. Demetriades, M. K. Hamdan, et al., “Structural Basis for Inhibition of the Fat Mass and Obesity Associated Protein (FTO),” Journal of Medicinal Chemistry 56, no. 9 (2013): 3680–3688.

[389] W. Xu, H. Yang, Y. Liu, et al., “Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases,” Cancer Cell 19, no. 1 (2011): 17–30.

[390] P. Xiao, Z. Duan, Z. Liu, et al., “Rational Design of RNA Demethylase FTO Inhibitors With Enhanced Antileukemia Drug-Like Properties,” Journal of Medicinal Chemistry 66, no. 14 (2023): 9731–9752.

[391] C. Dobie, A. P. Montgomery, R. Szabo, H. Yu, and D. Skropeta, “Synthesis and Biological Evaluation of Selective Phosphonate-Bearing 1,2,3-Triazole-Linked Sialyltransferase Inhibitors,” RSC Medicinal Chemistry 12, no. 10 (2021): 1680–1689.

[392] J. D. W. Toh, L. Sun, L. Z. M. Lau, et al., “A Strategy Based on Nucleotide Specificity Leads to a Subfamily-Selective and Cell-Active Inhibitor of N(6)-Methyladenosine Demethylase FTO,” Chemical Science 6, no. 1 (2015): 112–122.

[393] S. Kuttikrishnan, K. S. Prabhu, and A. H. Al Sharie, “Natural Resorcylic Acid Lactones: A Chemical Biology Approach for Anticancer Activity,” Drug Discovery Today 27, no. 2 (2022): 547–557.

[394] W. Aik, J. S. Scotti, H. Choi, et al., “Structure of human RNA N⁶-Methyladenine Demethylase ALKBH5 Provides Insights Into Its Mechanisms of Nucleic Acid Recognition and Demethylation,” Nucleic Acids Research 42, no. 7 (2014): 4741–4754.

[395] X. Liu, P. Li, Y. Huang, et al., “M(6)A Demethylase ALKBH5 Regulates FOXO1 mRNA Stability and Chemoresistance in Triple-Negative Breast Cancer,” Redox Biology 69 (2024): 102993.

[396] S. Pan, J. Zhu, P. Liu, et al., “FN1 mRNA 3'-UTR Supersedes Traditional Fibronectin 1 in Facilitating the Invasion and Metastasis of Gastric Cancer Through the FN1 3'-UTR-let-7i-5p-THBS1 Axis,” Theranostics 13, no. 14 (2023): 5130–5150.

[397] B. Li, W. Shen, H. Peng, et al., “Fibronectin 1 Promotes Melanoma Proliferation and Metastasis by Inhibiting Apoptosis and Regulating EMT,” OncoTargets and Therapy 12 (2019): 3207–3221.

[398] S. Zhang, B. S. Zhao, A. Zhou, et al., “m(6)A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-Like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program,” Cancer Cell 31, no. 4 (2017): 591–606.e6.

[399] A. Malacrida, A. Di Domizio, A. Bentivegna, et al., “MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell Lines,” Biology (Basel) 11, no. 1 (2022): 70.

[400] P. Tabnak, A. Hasanzade Bashkandi, M. Ebrahimnezhad, and M. Soleimani, “Forkhead Box Transcription Factors (FOXOs and FOXM1) in Glioma: From Molecular Mechanisms to Therapeutics,” Cancer Cell International 23, no. 1 (2023): 238.

[401] C. Shen, Y. Sheng, A. C. Zhu, et al., “RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia,” Cell Stem Cell 27, no. 1 (2020): 64–80.e9.

[402] S. Komal, A. Gohar, S. Althobaiti, et al., “ALKBH5 Inhibitors as a Potential Treatment Strategy in Heart Failure-Inferences From Gene Expression Profiling,” Frontiers in Cardiovascular Medicine 10 (2023): 1194311.

[403] S. Wu, J. Yun, W. Tang, et al., “Therapeutic m(6)A Eraser ALKBH5 mRNA-Loaded Exosome-Liposome Hybrid Nanoparticles Inhibit Progression of Colorectal Cancer in Preclinical Tumor Models,” ACS Nano 17, no. 12 (2023): 11838–11854.

[404] Y. Tang, C. Jia, H. Ning, et al., “Breaking Tumor Chemoresistance via METTL3 Regulation Enhanced by Sequential Delivery of Dexamethasone,” ACS Applied Material Interfaces 17, no. 32 (2025): 45555–45568.

[405] X. M. Liu, J. Zhou, Y. Mao, Q. Ji, and S. B. Qian, “Programmable RNA N(6)-Methyladenosine Editing by CRISPR-Cas9 Conjugates,” Nature Chemical Biology 15, no. 9 (2019): 865–871.

[406] X. Ying, X. Jiang, H. Zhang, et al., “Programmable N6-Methyladenosine Modification of CDCP1 mRNA by RCas9-Methyltransferase Like 3 Conjugates Promotes Bladder Cancer Development,” Molecular Cancer 19, no. 1 (2020): 169.

[407] J. Tao, D. E. Bauer, and R. Chiarle, “Assessing and Advancing the Safety of CRISPR-Cas Tools: From DNA to RNA Editing,” Nature Communications 14, no. 1 (2023): 212.

[408] J. H. Lee, J. Hong, Z. Zhang, et al., “Regulation of Telomere Homeostasis and Genomic Stability in Cancer by N (6)-Adenosine Methylation (m(6)A),” Science Advances 7, no. 31 (2021): eabg7073.

[409] J. Li, Z. Chen, F. Chen, et al., “Targeted mRNA Demethylation Using an Engineered dCas13b-ALKBH5 Fusion Protein,” Nucleic Acids Research 48, no. 10 (2020): 5684–5694.

[410] Z. Xia, M. Tang, J. Ma, et al., “Epitranscriptomic Editing of the RNA N6-Methyladenosine Modification by dCasRx Conjugated Methyltransferase and Demethylase,” Nucleic Acids Research 49, no. 13 (2021): 7361–7374.

[411] X. Ying, Y. Huang, B. Liu, et al., “Targeted M(6)A Demethylation of ITGA6 mRNA by a Multisite dCasRx-m(6)A Editor Inhibits Bladder Cancer Development,” Journal of advanced research 56 (2024): 57–68.

[412] J. Zhao, B. Li, J. Ma, W. Jin, and X. Ma, “Photoactivatable RNA N(6) -Methyladenosine Editing With CRISPR-Cas13,” Small 16, no. 30 (2020): e1907301.

[413] H. Tang, S. Han, Y. Jie, et al., “Enhanced or Reversible RNA N6-Methyladenosine Editing by Red/Far-red Light Induction,” Nucleic Acids Research 53, no. 5 (2025): gkaf181.

[414] X. Chen, Q. Zhao, Y. L. Zhao, et al., “Targeted RNA N(6) -Methyladenosine Demethylation Controls Cell Fate Transition in Human Pluripotent Stem Cells,” Advanced Science (Weinheim) 8, no. 11 (2021): e2003902.

[415] H. Shi, Y. Xu, N. Tian, M. Yang, and F. S. Liang, “Inducible and Reversible RNA N(6)-Methyladenosine Editing,” Nature Communications 13, no. 1 (2022): 1958.

[416] Y. Xu, Y. Wang, and F. S. Liang, “Site-Specific M(6) A Erasing via Conditionally Stabilized CRISPR-Cas13b Editor,” Angewandte Chemie 62, no. 43 (2023): e202309291.

[417] Z. Zhang and X. J. Wang, “N(6)-Methyladenosine mRNA Modification: From Modification Site Selectivity to Neurological Functions,” Accounts of Chemical Research 56, no. 21 (2023): 2992–2999.

[418] X. Li, S. Ma, Y. Deng, P. Yi, and J. Yu, “Targeting the RNA M(6)A Modification for Cancer Immunotherapy,” Molecular Cancer 21, no. 1 (2022): 76.

[419] Z. Ren, J. He, X. Huang, et al., “Isoform Characterization of M(6)A in Single Cells Identifies Its Role in RNA Surveillance,” Nature Communications 16, no. 1 (2025): 5828.

[420] H. Song, X. Feng, H. Zhang, et al., “METTL3 and ALKBH5 Oppositely Regulate M(6)A Modification of TFEB mRNA, Which Dictates the Fate of Hypoxia/Reoxygenation-Treated Cardiomyocytes,” Autophagy 15, no. 8 (2019): 1419–1437.

[421] W. Mao, Q. Jiang, Y. Feng, et al., “TRIM21-Mediated METTL3 Degradation Promotes PDAC Ferroptosis and Enhances the Efficacy of Anti-PD-1 Immunotherapy,” Cell Death & Disease 16, no. 1 (2025): 240.

[422] H. Chen, N. Xiao, C. Zhang, et al., “JMJD6 K375 acetylation Restrains Lung Cancer Progression by Enhancing METTL14/m6A/SLC3A2 Axis Mediated Cell Ferroptosis,” Journal of Translational Medicine 23, no. 1 (2025): 233.

[423] K. Wang, G. Wang, G. Li, et al., “m6A Writer WTAP Targets NRF2 to Accelerate Bladder Cancer Malignancy via m6A-Dependent Ferroptosis Regulation,” Apoptosis 28, no. 3-4 (2023): 627–638.

[424] H. Feng, X. Yuan, S. Wu, et al., “Effects of Writers, Erasers and Readers Within miRNA-Related m6A Modification in Cancers,” Cell Proliferation 56, no. 1 (2023): e13340.

[425] Q. Yi, Y. Liao, W. Sun, et al., “m6A Modification of Non‑Coding RNA: Mechanisms, Functions and Potential Values in Human Diseases (Review),” International Journal of Molecular Medicine 56, no. 4 (2025): 164.

[426] S. Dong, J. Pang, Y. Wang, et al., “RNA M(6)A Dynamics Promote Transcription and RNA Stability of Bivalent Genes During iPSC-Induced Generation of Human Lung Progenitors,” Cell Reports 44, no. 6 (2025): 115802.

[427] Y. Cao and W. Guo, “Role of METTL14 in Cardiomyocyte Pyroptosis in Mice With Heart Failure by Regulating miR-221-3p RNA Methylation,” International Immunopharmacology 149 (2025): 114172.

[428] D. Jang, C. Hwa, S. Kim, et al., “RNA N(6)-Methyladenosine-Binding Protein YTHDFs Redundantly Attenuate Cancer Immunity by Downregulating IFN-γ Signaling in Gastric Cancer,” Advanced Science (Weinheim) 12, no. 3 (2025): e2410806.

[429] J. Gleeson, S. U. Madugalle, C. Y. Wan, et al., “Isoform-level Profiling of M(6)A Epitranscriptomic Signatures in human Brain,” Science Advances 11, no. 32 (2025): eadp0783.

[430] S. Delaunay, G. Pascual, B. Feng, et al., “Mitochondrial RNA Modifications Shape Metabolic Plasticity in Metastasis,” Nature 607, no. 7919 (2022): 593–603.

[431] S. Feng and M. J. Koziol, “Unraveling Brain Complexity: From Single-Cell to Spatial M(6)A Technologies,” Trends in Genetics 42, no. 1 (2025): 101–113.

[432] S. E. Ogbe, J. Wang, Y. Shi, et al., “Insights Into the Epitranscriptomic Role of N(6)-Methyladenosine on Aging Skeletal Muscle,” Biomedicine & Pharmacotherapy 177 (2024): 117041.

[433] Y. Liu, M. Shi, X. He, et al., “LncRNA-PACERR Induces Pro-Tumour Macrophages via Interacting With miR-671-3p and m6A-reader IGF2BP2 in Pancreatic Ductal Adenocarcinoma,” Journal of Hematology & Oncology 15, no. 1 (2022): 52.

[434] Y. Guo, Y. Guo, C. Chen, et al., “Circ3823 Contributes to Growth, Metastasis and Angiogenesis of Colorectal Cancer: Involvement of miR-30c-5p/TCF7 Axis,” Molecular Cancer 20, no. 1 (2021): 93.

[435] X. Ren, R. Deng, K. Zhang, Y. Sun, Y. Li, and J. Li, “Single-Cell Imaging of M(6) A Modified RNA Using M(6) A-Specific in Situ Hybridization Mediated Proximity Ligation Assay (m(6) AISH-PLA),” Angewandte Chemie 60, no. 42 (2021): 22646–22651.

[436] M. Song, J. Wang, J. Hou, et al., “Multiplexed in Situ Imaging of Site-Specific m6A Methylation With Proximity Hybridization Followed by Primer Exchange Amplification (m6A-PHPEA),” ACS Nano 18, no. 40 (2024): 27537–27546.

[437] C. J. Sheehan, B. F. Marayati, J. Bhatia, and K. D. Meyer, “In Situ Visualization of m6A Sites in Cellular mRNAs,” Nucleic Acids Research 51, no. 20 (2023): e101.

[438] Q. Zhang, Y. Dai, X. Teng, and J. Li, “Visualization and Quantification of Single-Base M(6)A Methylation,” Angewandte Chemie 64, no. 6 (2025): e202420977.

[439] C. Wilson, P. J. Chen, Z. Miao, and D. R. Liu, “Programmable M(6)A Modification of Cellular RNAs With a Cas13-Directed Methyltransferase,” Nature Biotechnology 38, no. 12 (2020): 1431–1440.

[440] X. Luo, H. Li, J. Liang, et al., “RMVar: An Updated Database of Functional Variants Involved in RNA Modifications,” Nucleic Acids Research 49, no. D1 (2021): D1405–d1412.

[441] Z. Liang, H. Ye, J. Ma, et al., “m6A-Atlas v2.0: Updated Resources for Unraveling the N6-Methyladenosine (m6A) Epitranscriptome Among Multiple Species,” Nucleic Acids Research 52, no. D1 (2024): D194–d202.

[442] S. Liu, L. Chen, Y. Zhang, et al., “M6AREG: M6A-Centered Regulation of Disease Development and Drug Response,” Nucleic Acids Research 51, no. D1 (2023): D1333–d1344.

[443] S. Deng, H. Zhang, K. Zhu, et al., “M6A2Target: A Comprehensive Database for Targets of m6A Writers, Erasers and Readers,” Brief Bioinformatics 22, no. 3 (2021): bbaa055.

[444] M. Tarullo, G. Fernandez Rodriguez, and A. Iaiza, “Off-Target Inhibition of Human Dihydroorotate Dehydrogenase (hDHODH) Highlights Challenges in the Development of Fat Mass and Obesity-Associated Protein (FTO) Inhibitors,” ACS Pharmacology & Translational Science 7, no. 12 (2024): 4096–4111.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.